Ручная коса Мороцкого

Использование: в сельскохозяйственном машиностроении, в частности в конструкциях ручных кос. Сущность изобретения: для повышения безопасности и увеличения сбора скашиваемых культур коса имеет полотно 1 и гребень 3, установленный на верхней стороне полотна и проходящий вдоль бурта 2. Нижняя строка полотна снабжена несколькими гребнями 4, расположенными у наружной кромки косы и изогнутыми по окружности радиуса, равного древку косы. Выпуклость гребней направлена к наружной кромке косы. 6 ил.

Приспособление к косе для уборки зерновых культур

Befestigungsvorrichtung fuer Sensenblaetter

TREATMENT FOR THE REDUCTION OF EDEMA AND MUSCLE DAMAGE.

Neuartiges Sensenblatt.

Sense.

Sense.

Verfahren zur Herstellung von Sensenklingen.

Sense.

Sense

Blade of forgery

КОСА

Коса, содержащая жестко соединенные между собой стальное лезвие, полотно, обух и стальную пятку, отличающаяся тем, что полотно и обух выполнены из полимерного материала, при этом ширина лезвия по всей его длине постоянна, а ее отношение к ширине полотна в средней части выбрано из соотношения: 0,15÷0,5.

СПОСОБ СКАШИВАНИЯ

... 1. Способ скашивания растений косой, отличающийся тем, что с целью повышения эффективности, производительности, удобства, расширения эксплуатационных возможностей, скашивают косой с прямой режущей кромкой. 2. Способ по п.1, отличающийся тем, что, с целью повышения производительности, скашивают косой с несколькими режущими кромками. 3. Способ пп.1 и 2, отличающийся тем, что, с целью повышения эффективности и удобства, скашивают косой на опорных роликах. 4. Способ по пп.1-3, отличающийся тем, что, с целью повышения эффективности и удобства, скашивают косой на опорной тележке. 5. Способ по пп.1-4, отличающийся тем, что, с целью повышения эффективности и удобства, скашивают косой на опорной тележке с сидением. 6. Способ по пп.1-5, отличающийся тем, что, с целью повышения производительности, эффективности, удобства, расширения эксплуатационных возможностей, скашивают относительным движением тележки с косой.

КОСА

... 1. Коса с прямой режущей кромкой, опорой, рукоятью для скашивания растений, отличающаяся тем, что она выполнена с быстросъемными режущими элементами. 2. Коса по п.1, отличающаяся тем, что она выполнена с роликовой опорой. 3. Коса по пп.1 и 2, отличающаяся тем, что она выполнена с опорами на плечи косца. 4. Коса по пп.1-3, отличающаяся тем, что она выполнена с возможностью рабочего перемещения по направляющим, перемещаемым на колесной тележке, фиксированной на теле косца.

An improved scythe

... 753,493. Scythes. WALTON A. R. PELLEW-, and BARRY, R. M. D., [trading as GENERAL & OVERSEAS TRADERS]. Nov. 1, 1954 [Aug. 1, 1953], No. 21398/53. Class 6 (3). A scythe blade 10 is adjustably mounted relative to a snathe by means of a shank 13 which fits in a slot 17 of a boss 15 provided with a serrated face 16 which co-operates with a similar face 21 on a boss 19 integral with a bar 18 which is attached to the snathe. The blade is secured relative to the snathe by means of a bolt 22. In a modification, the boss 19 and bar 18 are made in separate parts. The bolt 22 may be formed integrally with one of the bosses 15 or 19.

Carbon multistage pipe shaft which is used for high ground work tools

... 탄소섬유복합재료 시트를 뿌리부분이 넓고 끝부분이 좁은 테이퍼 형상으로 말아서 성형한 카본파이프(10)와 상기 카본파이프(10)의 끝부분 외주면에 부착 결합되는 금속재질의 파이프조인트(20), 그리고 상기 카본파이프(10)의 뿌리부분 외주면 위에 형성된 고무코팅층(12)을 포함하여 구성된 샤프트유닛(30)과 이를 다수 연결 구성한 고지작업구용 샤프트가 개시된다. 카본파이프(10)의 뿌리부분 외주면과 상기 고무코팅층(12) 사이에는 탄소섬유 복합재료 시트를 일정 간격으로 분할하여 테이핑 접착한 다수의 테이핑돌기(11)가 더 형성되며 돌기들은 적당한 변형력을 가진 고무코팅층(12)과 결합될 때 파이프의 뿌리로 갈수록 넓은 면적에서 적게 압착되고 덜 비틀리며, 파이프의 끝으로 갈수록 좁은 면적에서 많이 압착되면서 많이 비틀리는 변형)을 유도할 수 있다. 이때 매우 넓은 띠폭의 되밀림 방지 지지면이 형성된다. 이에 따라 알루미늄 압출파이프보다 훨씬 경량이며 고강도 재질인 카본파이프를 고지작업도구용 자루로 사용가능하고, 또한 고지작업 중에 샤프트를 앞으로 미는 동작을 취했을 때에도 인출된 카본파이프가 안으로 되밀려 들어가지 않아 매우 높은 상품성을 가진 고지작업구용 샤프트가 구현된다.

СПОСОБ СКАШИВАНИЯ РАСТЕНИЙ КОСОЙ С ПРЯМОЙ РЕЖУЩЕЙ КРОМКОЙ

Изобретение относится к сельскохозяйственному производству. Скашивание растений осуществляют рабочим движением косы с прямой режущей кромкой, при этом перемещение косы осуществляют на опорных роликах. Опирание косы при работе на ролики повышает производительность за счет устойчивости движения косы. 2 з.п. ф-лы, 3 ил.

РУЧНАЯ КОСА

Ручная коса содержит полотно, режущий контур и ручку. Режущий контур выполнен по циклоиде, длина которой равна длине режущего контура косы. На режущем контуре косы сделаны дополнительные вырезы, образованные отрезками пересекающихся между собой нескольких дополнительных циклоид, точки пересечения которых образуют пилообразный профиль. Пилообразный профиль огибает режущий циклоидальный контур косы в точках О, N, А, В. С, D. Касательные к дополнительным циклоидам в точках их пересечения имеют углы меньше углов трения травы о поверхность режущего контура косы. При таком выполнении снижаются энергозатраты, повышается производительность кошения. 1 ил.

КОСА

Полезная модель относиться к ручным режущим уборочным орудиям и может быть использована для скашивания сорной растительности, в том числе мелких кустарников толщиной до 3 см и более. Предлагаемой полезной моделью решается задача увеличения количества функций косы путем увеличения ее веса. С этой целью тело косы имеет скругленную режущую кромку с пятой, на которой установлена крепежная пластина с отверстиями. Одно из отверстий под болт служит для установки быстросъемных шайб, которые обеспечивают дополнительный вес косы. Что в свою очередь позволяет использовать косу для срезания мелких кустарников до 3 см и более, например тростник, камыш, малинник и т.п. Диаметр шайб не должен превышать размер пяты косы. Другие отверстия предназначены для крепления косовища.

Способ образования части, служащей для скрепления косы с косовищем у кос, изготовляемых штамповкой из листовой или тонкой полосовой стали

BEHANDLUNG ZUR ERMÄSSIGUNG VON ÖDEM UND MUSKELSCHÄDEN.

Improvements in or relating to scythes

... 155,988. Taylor, W. H. Dec. 17, 1919. Scythes.-The point d of a scythe blade a is strengthened by extending the ordinary back or stiffening rib b so as to project beyond the extremity of the blade. The extended portion may be in one piece with the main rib or may be formed from a separate piece of metal.

Improvements in and relating to scythes

... 692,152. Making scythe blades. HUTTON & CO., Ltd., T. & J., and CLEGG, B. B. May 21, 1951 [June 12, 1950], No. 14630/50. Class 83 (ii). [Also in Group I] A scythe blade is made from straight bar stock 10, Fig. 8, with a stiffening rib 12 and having a cross-section which is substantially that of the finished blade. One end of a blank is cut obliquely to form a point 14, Fig. 3, and the blank is then heated and bent to curved form, Fig. 6. A length 12a of the stiffening rib is transferred by hammering to the opposite face of the blade near the point 14 or may be ground away. Irregularities in the cutting edge 13 are removed by hammering and the blade is then finished by hardening and grinding. A preformed tang 18 is attached by rivets 19.

Procedure for the production of scythes from rolled plate.

Cutting tool with back and thin blade

Нож для ручной косы

Полезная модель относится к области ножей для ручных сельскохозяйственных кос. Техническим результатом заявляемой полезной модели является повышение надежности ножа в работе за счет изменения формы его лезвия. Новым является то, что лезвие ножа выполнено по форме, близкой к форме лезвия «финского ножа», - острое и узкое лезвие на переднем конце постепенно расширяется и заканчивается на срезе перед пяткой. Укомплектованная таким ножом коса позволяет существенно повысить эффективность работы косца, при этом себестоимость ножа предлагаемой формы будет ниже, чем себестоимость ножа-прототипа. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 178 240 U1 (51) МПК A01D 1/02 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (52) СПК A01D 1/02 (2006.01) (21)(22) Заявка: 2017133589, 26.09.2017 (24) Дата начала отсчета срока действия патента: (73) Патентообладатель(и): Подшивалов Виктор Александрович (RU) Дата регистрации: 28.03.2018 (56) Список документов, цитированных в отчете о поиске: RU 2497340 C2, 10.11.2013. RU 2529728 C1, 27.09.2014. RU 97895 U1, 27.09.2010. SU 1802988 A1, 23.03.1993. (45) Опубликовано: 28.03.2018 Бюл. № 10 R U (54) Нож для ручной косы (57) Реферат: Полезная модель относится к области ножей для ручных сельскохозяйственных кос. Техническим результатом заявляемой полезной модели является повышение надежности ножа в работе за счет изменения формы его лезвия. Новым является то, что лезвие ножа выполнено по форме, близкой к форме лезвия «финского Стр.: 1 ножа», - острое и узкое лезвие на переднем конце постепенно расширяется и заканчивается на срезе перед пяткой. Укомплектованная таким ножом коса позволяет существенно повысить эффективность работы косца, при этом себестоимость ножа предлагаемой формы будет ниже, чем себестоимость ножа-прототипа. U 1 U 1 Адрес для переписки: 620023, г. Екатеринбург, ул. Рощинская, 48, кв. 396, Подшивалову В.А. 1 7 8 2 4 0 Приоритет(ы): (22) Дата подачи заявки: 26.09.2017 1 7 8 2 4 0 R ...

КОСА СЕЛЬСКОХОЗЯЙСТВЕННАЯ

Коса сельскохозяйственная, содержащая стальное полотно саблеобразной формы с ребром жесткости и режущим лезвием и пятку с привалочной плоскостью, отличающаяся тем, что пятка косы снабжена двумя выступами, расположенными в плоскостях, перпендикулярных привалочной, причем один из выступов имеет регулировочный винт.

Конструкция крепления косы к древку

Коса

Improvements in scythes

... 424,918. Scythes. WOODWARD, J. W., The Orchard, Belbroughton, and MOUNTFORD, P., Sandbourne, Kinver, near Stourbridge, both in Worcestershire. Jan. 10, 1934, No. 871. [Class 6 (iii)] To secure a scythe blade adjustably to its handle the tang 6 of the blade 5 extends into an opening in a metal ball 8 and is secured therein, this metal ball being clamped in the desired position between two members 11, 16, attached to the handle and each provided with a seating for the ball. The part of the tang 6 entering the ball 8 is preferably slightly tapered and its end is riveted over to secure the ball thereon : the ball may also be welded to the tang or secured by a screw and nut. The clamping member 11 is provided with an extension 12 to embrace the handle to which it is secured by bolts 13. The other member 16 is provided with a hooked portion 18 adapted to engage in a co-operating recess 15 on the member 11 to form a hinge connection, the two members being adapted to be drawn together about this ...

TREATMENT TO REDUCE EDEMA FOR BRAIN AND MUSCULATURE INJURIES

Administration of a Corticotropin-Releasing Factor (or a salt or analog thereof) decreases the leakage of blood components into brain tissue produced by various adverse medical condition and reduces bleeding when muscle tissues are cut and handled, such as in plastic and reconstructive surgery. A method of treating a patien t for injury to or disease of the brain, central nervous system, or musculature in which edema is a factor comprises administering to the patient a Corticotropin-Releasing Factor (or a salt or analog) in an amount effective to decrease vascular permeabili ty in the injured or diseased brain, nervous system tissue or musculature, and thereby to reduce edema. Administration in accordance with the method can be about two hours before surgery, or can be up to three days after injury.

Portable-type obstacle removal device

Faulx and its manufactoring process

Ｗ型簡単草刈器具

... 【課題】草刈作業の体力負担が少なく、取り換え可能なカッター刃を使うことにより安価で切れ味のよいＷ型簡単草刈器具を提供する。【解決手段】交換可能なカッター草刈刃を下面刈刃受けプレート２、上面刈刃押えプレート３にＷ型に取り付け、中央部に軽量パイプ握り柄１を地面に対して垂直方向へ６０度〜８５度の範囲に接続した。【選択図】図１ ...

РУЧНАЯ КОСА

Ручная коса, включающая длинный изогнутый нож на длинной рукоятке для срезывания травы, злаков, отличающаяся тем, что, с целью снижения затрат энергии и повышения производительности при кошении путем оптимизации параметров режущего контура и углов входа и выхода режущего контура предлагаемого устройства, на режущем контуре косы установлен оптимальный по форме профиль в виде циклоиды обеспечивающий минимальное время пребывания травы на режущей кромке лезвия косы и максимальную скорость схода срезанной травы с режущей кромки циклоиды, причем на входе режущей кромки контура косы угол φ меньше, а выходе режущей кромки угол φ больше угла трения травы о стальной режущий контур.

Коса со съемным режущим клинком

Improvements in and relating to scythe blades

... 481,386. Scythes. MOUNTFORD & SONS, Ltd., F., MOUNTFORD, F. C. O., and MOUNTFORD, H. H. Jan. 11, 1937, No. 752. [Class 6 (iii)] To stiffen the end of the blade of a scythe the junction of the stiffening groove 1 at the tip of the blade and the offset portion or grist 2 is arranged with staggered end wall portions 3, 4. The groove 1 is preferably given a sinuous form.

Improvement to the manufacture of false

Handle of sophisticated forgery

РУЧНАЯ КОСА

Ручная коса для срезывания травы и злаков содержит полотно, режущий контур и ручку. Новшество изобретения в том, что режущий контур косы изготовлен по циклоиде заданным радиусом производящего круга, причем в начале режущего контура циклоиды угол к траектории циклоиды меньше, а в конце режущего контура угол к траектории циклоиды больше угла трения травы о сталь. Техническим результатом изобретения является снижение затрат энергии и повышение производительности при кошении. 1 ил.

РУЧНАЯ КОСА

Ручная коса, содержащая полотно, косьё, отличающаяся тем, что на косье закреплены ручки под правую и левую руки косаря, выполненные с возможностью вращения вокруг своих осей, причем ручка под правую руку закреплена в средней части косья, с возможностью перемещения вверх-вниз и вокруг косья в радиальном направлении, а ручка под левую руку закреплена в торце верхней части косья, причем ручки выполнены цилиндрической формы с двумя радиальными симметричными относительно центральной части углублениями, копирующими рельеф ладоней и сквозными отверстиями в торцевой части для размещения на осях вращения.

PУЧHAЯ KOCA MOPOЦKOГO

Snow shovel has handle consisting of two tubular sections and bar probe made up of jointed sections folded zigzag-fashion which fits into sections of handle

The snow shovel has a handle consisting of two tubular sections (2, 11). A bar probe (3) made up of jointed sections folded zigzag-fashion fits into the sections of the handle.

Adjustable scythe

Manufactoring process of the forgeries

Improved false

Forgery with brought back edge

Sense mit auswerchselbarem Blatt

Waldkultursense

Improvements in scythe and like blades

... 440,972. Making scythes. HAVENHAND, W. H., 24, Meadow Bank Avenue, Sheffield, Aug. 9, 1934, No. 23011. [Class 83 (ii)] [See also Group I] To strengthen the tip of a scythe or like blade it is reinforced by fused metal integral with the blade and the blade back. The fused metal tip 4 extends from the riveted back 2, which is preferably undercut as shown at 3, to the point 6 of the blade and is ground to form a cutting edge 6a.

Sickle

Reaping hook

safety cover of sickle

Scythe for anglers' use

... 734,514. Scythes. AXE, W. Sept. 22, 1953 [June 23, 1952], No. 15707/52. Class 6 (3). A scythe for angler's use comprises a short curved blade 10 provided with a screwed shank 12 for attachment to a socket 13 in the end of a handle 14 such as a landing net handle. The handle may be provided with a screwed shank and the blade may be provided with a screwed socket.

Carbon multistage pipe shaft which is used for high ground work tools

Electric palm tree harvesting machine

An electric palm tree harvesting machine comprising a lopper tube and a main housing disposed at a front end of the lopper tube. An upper housing of the main housing is provided with a transversal pipe portion for assembling the lopper tube, and a driving bevel gear and a driven bevel gear. The bottom of the driven bevel gear is eccentrically connected to a link that is also connected to a sickle. The transversal pipe portion is defined with a notch, a front bearing of a rotary shaft of the driving bevel gear is located at the front of the notch and is received in a hole corresponding to the transversal pipe portion, and a rear bearing of the rotary shaft is disposed in the transversal pipe portion, which can avoid forming a unilateral gear and prevent the bearing from being damaged by uneven stress.

Scythe, straw knife, and the like

Stellvorrichtung fuer Sensen

Improvements in or relating to scythes, strawknives and the like

... 301,738. Gonyk, I. Dec. 3, 1928. [A Specification was laid open to inspection under Sect. 91 of the Acts, Dec. 3, 1928]. Addition to 245,022. Scythes.-A scythe, draw-knife, or the like with h detachable extra blade as described in the parent Specification has the detachable blade 3 secured by a covering rail 5 provided with wedging tongues 7 adapted to pass under U-shaped stamped-out parts in the main blade, thus holding the detachable blade-which is furnished with recesses 4 to fit against the parts 2-firmly against the main blade. The front end of the covering rail and of the detachable blade fit under a bent strap 9 on the main blade. The parts 2 may be riveted to or otherwise attached to the blade. Covering pockets to prevent the intrusion of dirt may be formed on the rail above the slots around the tongues 7. The pockets may be open at one side to permit the rail to be moved laterally on the parts 2 into position for its wedging movement. T-shaped members with appropiate locking devices ...

Improvements in or relating to scythes and like implements

... 899,457. Handles for scythes. TYZACK & CO. Ltd., W. A. April 14, 1961 [April 14, 1960], No. 13504/60. Class 61. A tubular metal handle 12 is detachably secured to the tang 11 of a scythe blade by means comprising a reversible wedge shaped member 13 secured to and alongside an end length of the handle and lying longitudinally between the handle and tang, the tang having a bent over extremity 19 which interengages the member 13, and means clamping the tang to the wedgeshaped member and handle. The wedge-shaped member 13 is detachably secured medially of its length to the handle 12 by a bolt 15, which passes transversely through the member 13 and diametrically through the handle 12. The tongue 19 of the tang passes transversely through the member 13 and into the wall of the handle. The member 13 and tang 11 are clamped to the handle by a pair of opposing brackets 22, 23 and clamping bolts 24 (not shown), 25, the bracket 22 straddling the handle and the bracket 23 straddling the tang. The handle ...

TREATMENT TO REDUCE EDEMA FOR BRAIN AND MUSCULATURE INJURIES

Administration of a Corticotropin-Releasing Factor (or a salt or analog thereof) decreases the leakage of blood components into brain tissue produced by various adverse medical condition and reduces bleeding when muscle tissues are cut and handled, such as in plastic and reconstructive surgery. A method of treating a patient for injury to or disease of the brain, central nervous system, or musculature in which edema is a factor comprises administering to the patient a Corticotropin-Releasing Factor (or a salt or analog) in an amount effective to decrease vascular permeability in the injured or diseased brain, nervous system tissue or musculature, and thereby to reduce edema. Administration in accordance with the method can be about two hours before surgery, or can be up to three days after injury.

False, straw chopper and other like instruments

Process for the manufacture of the forgeries

DOUBLE-BLADED GRASS CUTTING SICKLE CAPABLE OF CUTTING GRASS BY MOVING THE SICKLE FORWARD AND BACKWARD

PURPOSE: A double-bladed grass cutting sickle is provided, which can cut grass effectively when pushes or pulls the sickle. CONSTITUTION: A double-bladed grass cutting sickle comprises a blade part in which a first blade is formed in one side and three waves are formed in the second blade formed in the other side to obtain frictional force like the saw blade; a sickle handle fixing the end of the blade part; a thin steel plate which is attached to the upper end of the sickle handle and gives elasticity to the sickle when the sickle is moved to the front and back; and a reinforcing unit which is formed in the blade center and increases intensity of the sickle. COPYRIGHT KIPO 2010 ...

Improvements in or relating to scythes

... 186,180. Mountford, F. July 4, 1921. Scythes.-To strengthen the extreme point of a scythe, one or more corrugations constituting ribs or grooves b are formed lengthwise or otherwise on the surface of the blade.

Improvements in the Manufacture of Scythes.

... 100,206. Ebner, H. March 22, 1915, [Convention date]. Scythes.-The back-plate of a scythe is thinned off towards the point and turned through an angle of approximately 90 degrees. The plate is shaped for the attachment of the blade, which is then electrically welded to it, as shown in Fig. 5. The extra surface of metal available for welding at the point of the scythe minimizes the risk of burning during the welding operation.

Improvements in or relating to scythes, reaping-hooks, and the like

... 348,840. Scythes &c. ANDREW, R. H., 2, Woodland View, Dore, near Sheffield, and SORBY & SONS, Ltd., R., 139, Norfolk Street, Sheffield. April 15, 1930, No. 11859. [Class 6 (iii).] The point or the short front blunt end a of a scythe, reaping hook, or like cutting tool is strengthened by the provision on said point or end of a piece bent or turned round sharply to produce a part or parts lying parallel to and either in close contact with the blade or near thereto and not extending beyond the point of the blade. The piece may be an integral portion c of the blade bent over or it may be a separate piece e constituted of one or more parts of steel and applied to or over the front end a of the blade.

Improvements in or relating to scythes, straw-knives and like implements

... 245,022. Gonyk, I. July 13, 1925. Scythes. - In a scythe &c. of the kind with a cutting- blade c secured to a main blade a by means of a covering- rail e, the slots g have tapered edges in order to engage more satisfactorily the heads of the rivets b. The main blade has a projection i and, above the inner edge of rail e, a rib, both of which assist the alignment of the blades.

Improvements relating to scythe blades

... 586,184. Poison-depositing scythes. MOUNTFORD, P. Nov. 28, 1945, No. 23765/44. [Classes 6 (ii) and 6 (iii)] A scythe blade is provided with a perforated tube x through which a substance poisonous to bracken may be delivered, the tube being secured to the scythe blade at an angle to the .longitudinal axis of the latter, so that the poison may be delivered to the stems of the bracken during mowing. Referring to the drawings, an outer tube 7 is angularly disposed and affixed to a rigid arm 12 attached to the neck 3 of a scythe blade 1. A tube 4 suitably perforated, as at 6, is arranged coaxially within the tube 7 and separated therefrom by an annular space, the underside of the tube 7 having a narrow longitudinal slot extending throughout its length and disposed immediately below the perforations 6. A screw 9 closes one end of the tube 4 and also fixes it within the tube 7. A rubber tube 4a which may have a control tap connects the tube 4 with a poison container. The annular space is partially ...

Improvements in or relating to scythes

... 325,978. Taylor, W. H. Feb. 2, 1929. Scythes.-The blade a is strengthened at its point by turning its back edge b at right angles to the blade from the box to the extreme point. The edge may be turned up on the front or the rear surface of the blade. Specification 19065/88 is referred to.

Altitude operation of the sickle

Stamped [...] odds

Improvements brought to the tools of the false kind

SICKLE WHICH SIMPLY CUTS THE WEED OF THE SHORT LENGTH

PURPOSE: A sickle for cutting is provided, which enables a user to carry the sickle easily and to cut the weed cut firstly in the constant size while sitting down. CONSTITUTION: A sickle for cutting comprises: a supporting board(10) forming the sickle storage(11) on the surface to keep a sickle(20) in which a through-hole(22) is punched; a sickle fixing unit(13) which faces each other in order to insert and fix the sickle; a coupler(30) which performs coupling through the fixed hole(14) and the through-hole; an angle adjuster(50) inserted and fixed into a plurality of adjusting holes(40) to adjust the angle of the sickle. © KIPO 2009 ...

Scythe

A scythe comprises an elongated blade 7 sharpened along opposed edges, the blade being connected to a handle 1 by a frame 5a, 5b which has an open structure, minimising resistance to movement of the tool when swinging it through herbage in a cutting direction. The frame may be releasably connected to the blade by longitudinally spaced connections 8 giving balanced support for the blade. The blade may be curved in a direction substantially at right angles to the longitudinal edges of the blade and the blade, when viewed in a plan may have curved longitudinal edges 9 which taper inwardly in a forward and/or rearward direction.

POLE SICKLE CAPABLE OF PREVENTING DAMAGE TO A BLADE

PURPOSE: A pole sickle is provided to easily cut grass or the stem of crops using a blade. CONSTITUTION: A pole sickle comprises a pole(112) which is made of aluminum, a resin cap(114) which is detachably combined with the upper end of the pole, a handle(110) which comprises a connection member, a main body which is formed with multiple blades in the longitudinal direction, and a blade(120) which comprises a pole insertion hole and is formed with a bent portion. COPYRIGHT KIPO 2013 ...

SICKLE FOR REMOVING WEEDS

The present invention relates to a sickle (1) which cuts plants including crops or weeds. Gap maintaining parts (5) are formed to protrude downwards from a lower portion of a main body (3) in the shape of a plate having an upper portion, which is joined to a shaft (2) and has a blade (4). The blade (4) comprises a pair of inclined blades (41) formed on both front and back lateral sides of the main body (3) in the shape of a plate. The gap maintaining parts (5) comprise a number of separation pieces (51) formed to be individually separated and to protrude downwards. The separation piece (51) is formed to be curved downwards while becoming thinner from the center toward the both front and back lateral sides. The main body (3) has a foot protection unit (31) to protect a user′s feet during use of the sickle as the main body (3) is formed on one side, perpendicular to locations of the inclined blades (41) on a front side and a rear side, to be blunt without the blade (41). According to the ...

Scythe

A scythe which comprises an elongated blade 7 having forward and rearward ends and sharpened opposed side edges 9, the blade being connected to a handle 1 by a frame which has an open structure minimising resistance to movement of the scythe when swinging it through herbage in a cutting direction. The blade is upwardly curved in the forward and rearward direction so that the forward and rearward ends of the blade are lifted from the ground in use. The upward curve of the forward and rearward ends of the blade helps to reduce any tendency for the blade to be clogged when swung through different types of herbage and assists the user to vary the angle of attack. An arm support may be mounted to the handle by way of adjustable means. The frame may comprise at least two struts 5a, 5b which may have sharpened or tapered edges in the cutting direction of the blade.

Improved blade for scythes

... 664,163. Scythes. STENSEN, Ltd. Jan. 25, 1950 [Jan. 25, 1949], No. 2046/49. Class 6(iii) A scythe-blade is of arcuate cross-section in a direction perpendicular to its cutting edge 6 and is of substantially uniform thickness over the portion to the rear of the edge. The blade has a convex underface 1 and a concave upper surface 2 and is formed with a rib 7 at its rear edge. The edge 6 terminates short of the pointed end 4 of the blade, which is fcrmed by a tapered part 8 of the rib 7. A tang 9 is formed at the handle end of the blade, the adjacent edge 3 being cut away.

Improvements in Scythes.

... 3420. Grote, F. Feb. 10, 1910, [Convention date]. Hinged handles; locking-keys for socket fixings.-In a scythe, the blade holder c is adjustably pivoted on the handle-bar b and the blade is provided with a curved tang g adjustably secured in a slot in the holder c. The tang g is fixed by means of a wedge h which is notched so that it may be used as a spanner. The holder c is pivoted at d and is adjustably fixed by means of a bolt e and curved slot f.

TREATMENT TO REDUCE EDEMA FOR BRAIN AND MUSCULATURE INJURIES

Sense mit zur Versteifung des Schneidblattes dienendem, zu diesem umgefaltetem Blechstreifen

Cutting assistance e.g. for engine, free cutting equipment and lawn mowers, has closed surface fastened under cutting device cover having arc-shaped-circle provided above plane section

The cutting assistance (2) has a closed surface fastened under a cutting device cover (3) having an arc-shaped-circle provided above a plane section. The radius of the cutting assistance is variable and being self adjustable based on the radius of the used tool or cut flight circle.

Scythe shaft for scythe, has two sections which may be separated during transport and joined back together for usage

The scythe shaft (1) is divided along its length into two sections (4,5) which are separable to ease transportation of the scythe shaft and can be joined back together for usage. External and internal connection devices (6,7) interconnect the two sections. An independent claim is also included for a scythe.

Method for preserving a whole mammalian organ

Solutions and suspensions comprising polymerized hemoglobin derived from human blood are disclosed. The solutions and suspensions may comprise cell culture medium, an enzyme (such as a protease), and/or a buffer. Processes of preparing the solutions and suspensions are also disclosed. The solutions and suspensions may be employed in methods of isolating mammalian cells, such as pancreatic islets, methods of preserving mammalian tissue and organs, methods of aiding the recovery of mammalian cells following their isolation, methods of maintaining mammalian cells, methods of propagating mammalian cells, and methods of treating a mammal with diabetes. 1. A method of preserving a whole mammalian organ , comprising contacting the whole organ with a solution comprising (a) polymerized hemoglobin derived from mammalian blood and (b) cell culture medium.2. A method according to claim 1 , where the organ is a human liver claim 1 , a human lung claim 1 , or a human kidney. This application is a divisional of U.S. application Ser. No. 13/041, 685, filed Mar. 7, 2011, which is a continuation of U.S. application Ser. No. 11/626,727, filed Jan. 24, 2007, which claims the benefit of U.S. Provisional Application No. 60/761,663, filed on Jan. 24, 2006.The entire teachings of the above applications are incorporated herein by reference.The application relates to the field of cell biology. In particular, the application relates to solutions, suspensions, methods, and processes useful for the isolation, culture, and transplantation of cells and tissues.The transplantation of cells, tissues, and organs holds great promise for the treatment of many diseases. For example, pancreatic islet transplantation can reverse insulin-dependent diabetes. Unfortunately, the procedure is hampered by a short supply of islets and a gradual loss of islet function after transplantation. The inconsistency of islet isolation outcomes has been a major limitation to widespread clinical application of islet ...

Method For The Analysis of Biological Samples Through Medical Ultrasound

A method for the conservation of human and animal anatomical parts, both normal and pathological, which comprises a hydration phase, immersion phase and packing phase. The hydration phase comprises immersing the anatomical part in and preserving and hydrating substance. The Immersion and Packing phases comprise immersing the specimen in a gel substance contained in a polyurethane, gel latex or silicone container that allows its analysis and study by ultrasound. 1. A method of preserving an anatomical specimen comprising the steps of:a. Hydrating the specimen in a moisturizing solution comprising a preservative;b. Immersing the specimen in a preservative gel; andc. Placing the specimen in an airtight container that is substantially invisible to ultrasound analysis2. The method of claim 1 , wherein the moisturizing solution comprises about 0.9% saline claim 1 , absolute alcohol and glycerin.3. The method of claim 2 , wherein the moisturizing solution comprises:a. about 200 cc 0.9% saline solution;b. about 100 cc absolute alcohol; andc. about 200 cc glycerin.4. The method of claim 2 , wherein the moisturizing solution further comprises at least one of formaldehyde claim 2 , bromide dimethyl benzyl ammonium lauryl or a combination thereof.5. The method of claim 4 , wherein the moisturizing solution comprises claim 4 , per 500 g of specimen:a. about 500 cc of 0.9% saline solution;b. about 200 cc of glycerin;c. about 20 cc of formaldehyde; andd. about 200 cc of absolute alcohol.6. The method of claim 4 , wherein the moisturizing solution comprises claim 4 , per 500 g of specimen:a. about 200 cc of 0.9% saline solution;b. about 100 cc of glycerin;c. about 20 cc of formaldehyde; andd. about 200 cc of absolute alcohol.7. The method of claim 1 , wherein the preservative gel comprises;a. Ultrasound gel;b. Formalin;c. Absolute Alcohol;d. Glycerin; ande. Carbapol.8. The method of claim 7 , wherein the preservative gel comprises claim 7 , per 500 g of specimen:a. about 1 gallon ...

TRANSPLANTS

The present invention relates to a method of reducing injury to cells, a tissue or organ to be explanted from a body and upon implantation into a body by administering a composition to the cell, tissue or organ, including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and (ii) an antiarrhythmic agent. The invention also provides a composition for reducing injury to vasculature ex vivo including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and (ii) an antiarrhythmic agent. 17-. (canceled)8. A method of reducing injury to vasculature that has been explanted or implanted by administering to the vasculature ex vivo a composition including:(i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and(ii) an antiarrhythmic agent.9. A method according to claim 10 , wherein the composition further includes at least one muscle relaxant.10. A method according to claim 11 , wherein the muscle relaxant is selected from the group consisting of a botulinum toxin claim 11 , myosin light chain kinase inhibitor claim 11 , calmodulin blocker claim 11 , calcium channel blocker claim 11 , nitric oxide donor claim 11 , dipyridamole claim 11 , beta blocker claim 11 , Na/H inhibitor claim 11 , high magnesium claim 11 , opioid claim 11 , phosphodiesterase inhibitors claim 11 , alpha-adrenergic receptor antagonists and Rho kinase inhibitors.11. A method according to claim 12 , wherein the phosphodiesterase inhibitor is selected from the group consisting of papaverine claim 12 , milrinone claim 12 , theophylline and dipyridamole.12. A method according to claim 12 , wherein the alpha-adrenergic receptor antagonist is phenoxybenzamine.13. A method according to claim 12 , wherein the Rho kinase inhibitor is selected from the group consisting of HA1077 and fausdil.14. A method according to claim 10 , wherein the composition is pre-mixed with the patient's blood.15. A method according to claim 10 , wherein ...

SYSTEMS AND METHODS FOR EX VIVO LUNG CARE

Methods and systems of maintaining, evaluating, and providing therapy to a lung ex vivo. The methods and systems involve positioning the lung in an ex vivo perfusion circuit; circulating a perfusion fluid through the lung, the fluid entering the lung through a pulmonary artery interface and leaving the lung through a left atrial interface; and ventilating the lung by flowing a ventilation gas through a tracheal interface. Maintaining the lung for extended periods involves causing the lung to rebreath a captive volume of air, and reaching an equilibrium state between the perfusion fluid and the ventilation gas. Evaluating the gas exchange capability of the lung involves deoxygenating the perfusion fluid and measuring a time taken to reoxygenate the perfusion fluid by ventilating the lung with an oxygenation gas. 1. A method of preserving a lung ex vivo comprising:circulating a perfusion fluid through the lung, the fluid entering the lung through a pulmonary artery interface and leaving the lung through a left atrial interface;ventilating the lung through a tracheal interface by flowing a captive volume of a ventilation gas back and forth between the lung and a variable volume chamber; andintroducing into the captive volume an additional flow of the ventilation gas and venting excess ventilation gas from the captive volume to maintain a predetermined composition of the ventilation gas and to maintain a minimum gas pressure of the captive volume.2. The method of claim 1 , wherein the ventilation gas includes a composition of oxygen claim 1 , carbon dioxide and an inert gas.3. The method of claim 2 , wherein the inert gas is nitrogen.4. The method of claim 1 , wherein a gas content of the perfusion fluid reaches an equilibrium level corresponding to the predetermined composition of the ventilation gas.5. The method of claim 1 , wherein the predetermined composition of the ventilation gas includes about 5-20% oxygen and about 2-10% carbon dioxide.6. The method of claim 5 ...

System, Method, and Device For Preserving Blood or its Components in Gas Medium Under Pressure

A system, method, and device for preserving blood and its components is described. The system and method generally include a device having a body defining a chamber, the chamber being configured to receive at least one bag containing blood or its components, the at least one bag being permeable to gas, for example, xenon. A cover is hermetically sealable to the body. An inlet is in fluid communication with the chamber. A pressure indicator is configured to indicate pressure in the chamber, the pressure indicator including a conduit containing a liquid. A portion of the conduit is transparent such that the liquid is visible. A source of pressurized gas, such as xenon, is provided to provide the pressurized gas to the chamber. 1. A method of preserving blood and its components , comprising: a body defining a chamber;', 'a cover hermetically sealable to the body;', 'an inlet configured to provide pressurized xenon gas to the chamber from a xenon gas source; and', 'a pressure indicator configured to indicate pressure in the chamber, the pressure indicator including a conduit containing a liquid;', 'wherein a portion of the conduit is transparent such that the liquid is visible;, 'providing a device, includingplacing at least one bag containing blood or its components disposed in the chamber, the at least one bag being permeable to xenon gas;hermetically sealing the chamber;supplying the chamber with xenon gas from the xenon gas source such that the xenon gas saturates the blood or its components.2. The method of claim 1 , wherein the xenon gas has a xenon content of no less than 65%.3. The method of claim 2 , wherein the xenon gas is supplied to the chamber until the pressure in the chamber reaches approximately 3.5 bars-5 bars.4. The method of claim 3 , further comprising placing the device in a refrigerator at a temperature of between 3° C.-6° C. after the chamber is supplied with approximately 3.5 bars-5 bars of pressure.5. The method of claim 1 , further comprising ...

INORGANIC PYROPHOSPHATE AND USES THEREOF

The present invention provides a new and improved sperm stimulating additive comprising a certain amount of inorganic pyrophosphate (PPi). Addition of PPi in the media for human/animal in vitro fertilization (IVF) improves fertilization rate; addition of PPi in the semen extender for farm animal artificial insemination (AI) may improve pregnancy rates; furthermore, mammalian oocytes matured in vitro in a medium including PPi attain improved fertilization and developmental potential, while embryos cultured in medium supplemented with PPi have improved development to blastocyst. 1. A sperm preservation media comprising inorganic pyrophosphate (PPi).2. The sperm preservation media of claim 1 , wherein the concentration of PPi is between about 1 μM and about 200 μM.3. The sperm preservation media of claim 1 , wherein the concentration of PPi is between about 1 μM and about 20 μM.4. The sperm preservation media of claim 1 , wherein the concentration of PPi is about 10 μM.5. The sperm preservation media of claim 1 , wherein said preservation media is used to preserve sperm from a porcine.6. A media for sperm processing comprising inorganic pyrophosphate (PPi).7. The media of claim 6 , wherein the concentration of PPi is between about 1 μM and about 200 μM.8. The media of claim 6 , wherein the concentration of PPi is between about 1 μM and about 20 μM.9. A media for in vitro fertilization (IVF) or artificial insemination (AI) comprising inorganic pyrophosphate (PPi).10. The media of claim 9 , wherein the concentration of PPi is between about 1 μM and about 200 μM.11. The media of claim 9 , wherein the concentration of PPi is between about 1 μM and about 20 μM.12. A semen sexing method claim 9 , comprising:(a) separating a mixed sperm suspension in a first culture medium into a population of x-bearing or y-bearing sperm with the aid of an elutant medium;(b) preserving the x-bearing or y-bearing sperm in a second culture medium,wherein, inorganic pyrophosphate (PPi) is added ...

Flush preservation solution

Flush preservation solution for the preservation of cells in the absence of a blood supply comprising: 149.-. (canceled)51. The flush preservation solution of claim 50 , comprising:iv) at least one component with calcium transport blocking properties and optionally additionally a component with an anti-calcium action activity.52. The flush preservation solution of claim 50 , wherein the calcium transport blocker is selected from the group consisting of nicardipine claim 50 , diltiazem claim 50 , verapamil claim 50 , nisoldipine claim 50 , chlorpromazine and trifluorperazine.53. The flush preservation solution of claim 50 , wherein the pH buffer is selected from the group consisting of a sodium phosphate buffer claim 50 , a potassium phosphate buffer claim 50 , and combinations thereof.54. The flush preservation solution of claim 50 , which additionally comprises:xiv) at least one component that acts reversibly upon crossbridge function in muscle.55. Flush preservation solution for heart preservation which comprises a combination of component classes given below of specific type listed{'sub': 2', '4, 'iii) NaHPO'}{'sub': 2', '4', '2, 'iii) NaHPO.2HO'}{'sub': 2', '4, 'iii) KHPO'}ii) Sucrose{'sub': '2', 'viii) MgCl'}{'sub': '2', 'viii) CaCl'}viii) NaCliv) Diltiazem57. A method for the preparation of a flush preservation solution as claimed in claim 50 , comprising adding components under pharmaceutically acceptable conditions in sequence to water claim 50 , and unstable components if any claim 50 , and dissolving claim 50 , adding any unstable components and making the solution nearly up to volume and finally making up to volume to regulate pH claim 50 , sterilising and cooling.58. The flush preservation solution of claim 50 , wherein said component with an anti-calcium action activity comprises a calcium chelator.59. The flush preservation solution of wherein component (ii) is present in an amount in the range 50-150 mmol/l claim 50 , each component (iii) is present ...

Compositions and methods for modulating ischemic injury

The invention is directed to methods of modulating ischemic injury in tissues and organs. The invention is further directed to methods of increasing time to ischemic injury in tissues and organs. Such methods utilize compositions comprising cells capable of modulating inflammatory responses, referred to herein as Inflammatory Response Modulating Cells (IRMCs). The IRMCs any be used directly or cell membranes derived from them may be used in practicing the methods of the invention. In addition, the IRMCs and IRMC membranes may be used alone or in combination with each other and/or in combination with various suitable active agents. 1. A method for modulating ischemic injury in tissues or organs comprising perfusing the tissue or organ with a composition selected from the group consisting of a composition comprising Inflammatory Response Modulating Cells (IRMCs) , a composition comprising IRMC membranes , and a composition comprising a combination of both IRMCs and IRMC membranes.2. A method for reducing ischemic injury in tissues or organs comprising perfusing the tissue or organ with a composition selected from the group consisting of a composition comprising IRMCs , a composition comprising IRMC membranes , and a composition comprising a combination of both IRMCs and IRMC membranes.3. A method for increasing the time to ischemic injury in tissues or organs comprising perfusing the tissue or organ with a composition selected from the group consisting of a composition comprising IRMCs , a composition comprising IRMC membranes , and a composition comprising a combination of both IRMCs and IRMC membranes.43. The method of any one of , , or wherein the IRMCs are selected from the group consisting of extraembryonic (EE) cells , extraembryonic HLA-G positive (EHP cells) , Amnion-derived Multipotent Progenitor (AMP) cells , Mesenchymal Stem Cells (MSC) , Sertoli cells , hepatic stellate cells , adult basal fibroblasts , donor matched unseparated bone marrow cells , donor ...

COAGULATION CONTROLLING AGENTS AND DEVICES COMPRISING THE SAME

A device and kit and method for controlling coagulation in a blood sample. The coagulation controlling agent is at least one of citrate, a protamine salt, its homologs and derivatives, benzamidine, or para-aminobenzamidine. Additives such as water soluble polymers and sugars are also contemplated. The device and kit comprise a container that contains an effective amount of thrombin and a coagulation controlling agent. The method combines thrombin and a coagulation controlling agent to stabilize thrombin or accelerate its activity in a blood sample. 1. A container for collecting serum , comprising a first end and a second end and at least one interior wall defining a reservoir portion for receiving the blood , wherein said reservoir comprises thrombin and at least one coagulation controlling agent , and a closure.2. The container of claim 1 , wherein said coagulation controlling agent is a polycarboxylic acid compound having a molecular weight of less than about 500 g/mol.3. The container of claim 2 , wherein said polycarboxylic acid compound is selected from the group consisting of citrate or isocitrate.4. The container of claim 2 , wherein a concentration of said coagulation controlling agent ranges from about 0.5 mM to about 100 mM of concentrated formulation.5. The container of claim 4 , wherein a concentration of said coagulation controlling agent ranges from about 1 mM to about 50 mM of concentrated formulation.6. The container of claim 1 , wherein said coagulation controlling agent is a protamine salt or a homolog or derivative thereof.7. The container of claim 6 , wherein a concentration of said coagulation controlling agent ranges from about 0.05 mg/mL to about 5 mg/mL of blood sample.8. The container of claim 7 , wherein a concentration of said coagulation controlling agent ranges from about 0.25 mg/mL to about 0.5 mg/mL of blood sample.9. The container of claim 1 , wherein said coagulation controlling agent is a weak competitive inhibitor of thrombin ...

COMPOSITIONS AND METHODS FOR IMPROVING THE QUALITY OF PROCESSED SPERM

The present invention relates to compositions and methods for the handling of processed sperm including samples that are freshly collected, those transported as fresh samples, samples that are frozen and thawed, those sorted into one or more subpopulations, and those that are otherwise processed or handled that impose trauma on the cell. Trauma can reduce the motility, fertility, viability and overall integrity of the sperm and reduce the ability to fertilize, produce an embryo and a healthy offspring. The present invention relates to novel compounds that can be added to the sperm cell sample to reduce the traumatic effects of physical stress during mild as well as extensive sperm cell processing, methods of using the compounds in standard sperm processing procedures, the end products made from these methods including sperm and embryos, as well as methods of using those end products in assisted reproductive biology techniques in animals. 1. A method of treating sperm cells during processing to improve cell integrity comprising the steps of:a. providing a sperm cell sample;b. processing the sperm cell sample; andc. adding one or more OSRs in the concentration range of 0.01 mg/ml to 5 mg/ml to the sperm cell sample to form a sperm cell composition.2. The method as claimed in claim 1 , further comprising the step of holding the sperm cell composition at a holding temperature without freezing for a period of time in the range of about 2 seconds to about a week following addition of the one or more OSRs.3. The method as claimed in claim 2 , wherein the holding period is selected from a range selected from the group of: about 2 sec to about 3 min; about 3 min to about 15 min; about 15 min to about 1 hr; about 1 hr to about 8 hrs; about 8 hrs to about 12 hrs; about 12 hrs to about 18 hrs; about 8 hrs to about 24 hrs; about 24 hrs to about 48 hrs; about 48 hrs to about 72 hrs;about 72 hrs to about 96 hrs; about 96 hrs to about 120 hrs; about 120 hrs to about 144 hrs; ...

PERFUSION SOLUTION

The invention provides a perfusion stock composition, for preserving a donor organ for transplantation, comprising: a source of 60 to 100 mM Na; a source of 10 to 20 mM K; a source of 5 to 10 mM Mg; a source of 0.25 to 0.75 mM Ca; 10 to 40 mM Tris(hydroxymethyl)aminomethane hydrochloride (Tris or THAM), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-(N-morpholino)propanesulfonic acid (MOPS), 2-(N-morpholino)ethanesulfonic acid (MES), N,/N-bis-(2-hydroxyethyl)-2-aminoethansulfonic acid (BES), or N/-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES); a source of 10 to 30 mM HCO; 1 to 30 mM glucose; 1 to 20 U/L insulin; 1 to 10 mM fructose diphosphate or a salt thereof; 1 to 40 mM aspartate or glutamate; 1 to 10 mM adenosine, cAMP or cGMP; 1 to 10 mM reduced glutathione; and 30 to 100 mM lactobionate or mannitol; and optionally a diluent. The invention also provides a perfusion composition, a kit, a method, and a perfusion apparatus, each related to the perfusion stock composition. 1. A perfusion stock composition , for preserving a donor organ for transplantation , comprising:{'sup': '+', '(a) a source of 60 to 100 mM Na;'}{'sup': '+', '(b) a source of 10 to 20 mM K;'}{'sup': '2+', '(c) a source of 5 to 10 mM Mg;'}{'sup': '2+', '(d) a source of 0.25 to 0.75 mM Ca;'}(e) 10 to 40 mM Tris(hydroxymethyl)aminomethane hydrochloride (Tris or THAM), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-(N-morpholino)propanesulfonic acid (MOPS), 2-(N-morpholino)ethanesulfonic acid (MES), N,N-bis-(2-hydroxyethyl)-2-aminoethansulfonic acid (BES), or N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES);{'sub': '3', 'sup': '−', '(f) a source of 10 to 30 mM HCO;'}(g) 1 to 30 mM glucose;(h) 1 to 20 U/L insulin;(i) 1 to 10 mM fructose diphosphate or a salt thereof;(j) 1 to 40 mM aspartate or glutamate;(k) 1 to 10 mM adenosine, cAMP or cGMP;(l) 1 to 10 mM reduced glutathione; and(m) 30 to 100 mM lactobionate or mannitol; and optionally(n) a ...

METHODS AND SYSTEMS FOR PROCESSING BIOLOGICAL FLUIDS

Methods and container systems for processing biological fluids are disclosed. The container systems include an inner container within an outer container. The inner container wall is made of a porous material of a selected porosity that allows certain components to pass through said porous wall but retains other components. A treating solution is introduced into the chamber of the outer container. 1. A container system for the treatment of a biological fluid comprising:a) an outer container including an interior chamber;b) an inner container suspended within said interior chamber of said outer container, said inner container comprising at least one wall defining an interior chamber of said inner container, wherein said wall is made of a porous material selected to allow passage of only certain components of said biological fluid across said wall;c) a port communicating with said interior chamber of said outer container; andd) at least one port communicating with said inner container.2. The container system of wherein said inner and outer containers are made a flexible polymeric material.3. The container system of wherein at least said outer container is made of rigid polymeric material.4. The container system of wherein said outer container includes a sealed peripheral edge and said inner container includes a peripheral edge captured within said outer container peripheral sealed edge.5. The container system of wherein said inner container is suspended within said interior chamber of said outer container.6. The container system of comprising a flow path that communicates with at least said one port and said inner chamber of said inner container.7. The container system of Claim wherein said inner container has a surface area of approximately 150-400 cmand said outer container has a surface area of approximately 250-600 cm.8. The container system of further comprising a sample pouch in flow communication with one of said interior chamber of said inner container and said ...

SAMPLE COLLECTION DEVICES WITH BLOOD STABILIZING AGENTS

Disclosed are devices for collecting and stabilizing blood or plasma and which contain an anti-coagulant, an antiplatelet agent, and a solubilization agent, and which may optionally include at least one other blood stabilization agent. Methods of making and using the devices in clinical medicine are also provided. 1. A device for collecting and stabilizing blood or plasma , comprising a first end and a second end and at least one interior wall defining a reservoir portion for receiving whole blood or plasma , and which comprises an anticoagulant , an antiplatelet agent comprising a prostaglandin , a phosphodiesterase inhibitor , a cyclooxygenase inhibitor , or a combination or two or more thereof , and a solubilization agent , wherein the anticoagulant and the antiplatelet agent are each present in an amount to stabilize the blood or plasma.2. The device of claim 1 , wherein the anticoagulant is selected from the group consisting of EDTA or a salt thereof claim 1 , oxalates claim 1 , citrate claim 1 , heparin claim 1 , a combination of citrate claim 1 , theophylline claim 1 , adenosine and dipyridamole (CTAD) claim 1 , sodium polyanethol sulfonate claim 1 , acid citrate dextrose claim 1 , and combinations of two or more thereof.3. The device of claim 1 , wherein the anticoagulant is present in a concentration of about 1 mM to about 200 mM claim 1 , relative to volume of the blood or plasma collected into the device.4. The device of claim 1 , wherein the antiplatelet agent is a prostaglandin.5. The device of claim 4 , wherein the prostaglandin comprises prostaglandin E1 claim 4 , prostaglandin E2 or a combination thereof.6. The device of claim 1 , wherein the prostacyclin comprises carbaprostacyclin claim 1 , beraprost claim 1 , iloprost claim 1 , 5 claim 1 ,6-dihydroprostacyclin claim 1 , ciprostene claim 1 , limaprost claim 1 , 13 claim 1 ,14-dehydro-15-cyclohexyl carbaprostacyclin claim 1 , taprostene claim 1 , and or a combination of two or more thereof.7. The ...

CRITICAL POINT DRYING SYSTEMS AND METHODS FOR IN SITU TISSUE PRESERVATION

Methods and systems for preserving tissues in situ using critical point drying are disclosed. Such methods and systems are particularly applicable to the preservation of a deceased body, such as a deceased person or animal, with or without removal of internal tissues or organs. A fixative can be perfused through the vascular system of the body while blood is removed from the body. The exterior of the body can also be immersed in a bath of fixative. The fixative in the vascular system and the bath can be replaced by subsequent washes of buffer, de-ionized water, and/or alcohol. The alcohol-infused and fixated body can be disposed in a pressure chamber and subjected to a critical point drying process using carbon dioxide. After the critical point drying process, the body is in a preserved state. 1. A method for preserving a deceased body or an organ thereof , the method comprising:perfusing the body or the organ with fixative delivered via the vascular system thereof, and, at a same time as the perfusing with fixative, exposing external surfaces of the body or the organ to fixative;after the perfusing with fixative, perfusing the body or the organ with liquid carbon dioxide delivered via the vascular system thereof;after the perfusing with liquid carbon dioxide, heating the body or the organ in a sealed chamber until the temperature and pressure in said chamber meet or exceed the critical point for carbon dioxide2. The method of claim 1 , further comprising claim 1 , after the heating claim 1 , exhausting the carbon dioxide from the body.3. The method of claim 1 , further comprising claim 1 , before the perfusing with liquid carbon dioxide and after the perfusing with fixative claim 1 , perfusing the body or the organ with deionized water delivered via the vascular system thereof.4. The method of claim 3 , further comprising claim 3 , after the perfusing with deionized water and before the perfusing with liquid carbon dioxide claim 3 , perfusing the body or the organ ...

HEPARAIN-BULKING AGENT COMPOSITIONS AND METHODS THEREOF

A free-flowing anti-coagulant powder composition, the anti-coagulant composition containing heparin and a bulking agent that is lyophilized or spray dried and ground into a powder. The powdered anti-coagulant composition can be dry filled into syringes and other blood collections systems for rapid dissolution and mixing with collected blood sample without agitation of the container. The formulation may also retain a portion of the initial moisture, which may improve the shelf life and stability of the composition. 1. A method of preparing a heparin-bulking agent composition , the method comprising:providing a heparin component and at least one bulking agent;dissolving the heparin component and the at least one bulking agent in a solution to form a heparin-bulking agent formulation;drying the heparin-bulking agent formulation to form a heparin-bulking agent composition having a solid mass; andgrinding the solid mass of the heparin-bulking agent composition to a particulate size such that the heparin-bulking agent composition comprises a free-flowing powder.2. The method of claim 1 , wherein the heparin component is a heparin salt chosen from lithium claim 1 , sodium claim 1 , calcium claim 1 , zinc or combinations thereof.3. The method of claim 2 , wherein the heparin component is provided as a solution claim 2 , an aqueous solution claim 2 , a solid material claim 2 , or a lyophilized heparin salt.4. The method of claim 2 , wherein the bulking agent is a water soluble material chosen from a sugar alcohol claim 2 , a carbohydrate claim 2 , a water-soluble polymer claim 2 , or combinations thereof.5. The method of claim 4 , wherein the water soluble material is chosen from mannitol claim 4 , trehalose claim 4 , raffinose claim 4 , sorbitol claim 4 , sucrose claim 4 , lactose claim 4 , polyvinylpyrollidone claim 4 , and combinations thereof.6. The method of claim 5 , wherein the water soluble bulking agent is provided as an aqueous solution or a solid material.7. The ...

ORGAN PROTECTION, PRESERVATION AND RECOVERY

This application describes compositions, methods of treatment, and methods of manufacturing a medicament for reducing injury or damage to cells, tissues or organs during ischemia, reperfusion, or following ischemia or trauma. The methods for reducing damage to a cell, tissue or organ comprise administering an effective amount of a composition including (i) a potassium channel opener or agonist and/or adenosine receptor agonist; and (ii) an antiarrhythmic agent. The methods may further include postconditioning the cell, tissue or organ. 1. A method for reducing damage to a cell , tissue or organ following ischemia comprising:administering an effective amount of a composition including (i) a potassium channel opener or agonist and/or adenosine receptor agonist; and (ii) an antiarrhythmic agent; andpostconditioning the cell, tissue or organ.2. A method according to claim 1 , wherein the composition further includes a delta-1-opioid receptor agonist.3. A method according to claim 2 , wherein the opioid is [D-Pen 2 claim 2 ,5]enkaphalin (DPDPE).4. A method according to claim 1 , wherein the adenosine receptor agonist is CCPA.5. A method for reducing damage to a cell claim 1 , tissue or organ following trauma comprising:administering an effective amount of a composition including (i) a potassium channel opener or agonist and/or adenosine receptor agonist; and (ii) an antiarrhythmic agent; andpostconditioning the cell, tissue or organ.6. A method for reducing damage to a cell claim 1 , tissue or organ during ischemia or reperfusion:administering an effective amount of a composition including (i) a potassium channel opener or agonist and/or adenosine receptor agonist; and (ii) an antiarrhythmic agent; andpostconditioning the cell, tissue or organ.7. A method for reducing damage to a cell claim 1 , tissue or organ following ischemia comprising administering to the cell claim 1 , tissue or organ an effective amount of a composition including (i) a potassium channel opener or ...

COMPOSITIONS AND METHODS FOR IMPROVING THE QUALITY OF PROCESSED SPERM

The present invention relates to compositions and methods for the handling of processed sperm including samples that are freshly collected, those transported as fresh samples, samples that are frozen and thawed, those sorted into one or more subpopulations, and those that are otherwise processed or handled that impose trauma on the cell. Trauma can reduce the motility, fertility, viability and overall integrity of the sperm and reduce the ability to fertilize, produce an embryo and a healthy offspring. The present invention relates to novel compounds that can be added to the sperm cell sample to reduce the traumatic effects of physical stress during mild as well as extensive sperm cell processing, methods of using the compounds in standard sperm processing procedures, the end products made from these methods including sperm and embryos, as well as methods of using those end products in assisted reproductive biology techniques in animals. 1199-. (canceled)200. An improved method of producing an embryo using ART by reducing stress on the sperm cell during sperm processing , comprising:a. forming a sperm cell composition by adding one or more OSRs in the concentration range of 0.01 to 5 mg/ml to the sperm cell sample,b. holding the sperm cell composition for a period of time,c. processing the sperm cell composition, andd. using the sperm cell composition in assisted reproductive techniques (ART).201. The method of producing an embryo according to the method of claim 200 , wherein the ART is selected from the group consisting of: in vitro fertilization (IVF) claim 200 , artificial insemination (AI) claim 200 , intracytoplasmic sperm injection (ICSI) claim 200 , multiple ovulation and embryo transfer (MOET) claim 200 , and other embryo transfer techniques.202. The method of producing an embryo according to the method of claim 200 , wherein two or more OSRs are added at multiple processing steps to further enhance the integrity of the sperm and the embryo made with the ...

Fluid for Suspended Animation

A method to increase the time a donated organ will remain viable prior to transplantation, where the method includes infusing into a human patient declared brain dead, using a first intravenous line, a fluorocarbon fluid comprising a chain length from 1 to about 20 carbon atoms, and optionally synchronously with said infusing, exsanguinating said patient using a second intravenous line. 1. A method to increase the time one or more donated organs will remain viable prior to transplantation , comprising:after a decision is made to terminate life-support for a human patient declared brain dead, infusing using a first intravenous line said patient with a fluorocarbon fluid comprising a chain length from 1 to about 20 carbon atoms; andharvesting said one or more organs.2. The method of claim 1 , further comprising synchronously with said infusing claim 1 , exsanguinating said patient using a second intravenous line.3. The method of claim 2 , further comprising synchronously with said infusing and said exsanguinating claim 2 , ventilating said patient with oxygen.4. The method of claim 1 , further comprising nebulizing said fluorocarbon fluid with 100 percent oxygen prior to said infusing.5. The method of claim 1 , wherein said fluorocarbon fluid comprises dodecafluoropentane.6. The method of claim 1 , further comprising:prior to said infusing, forming a composition comprising said fluorocarbon fluid in combination with an aqueous solution comprising sodium ions, potassium ions, calcium ions and magnesium ions.7. The method of claim 6 , wherein said aqueous solution further comprises chloride ions and bicarbonate ions.8. The method of claim 6 , wherein said aqueous solution further comprises one or more saccharides.9. The method of claim 6 , wherein said aqueous solution further comprises one or more amino acids or salts thereof.10. The method of claim 6 , wherein said aqueous solution further comprises one or more vitamins.11. The method of claim 6 , wherein said aqueous ...

METHODS AND COMPOSITIONS FOR PRESERVING TISSUES AND ORGANS

The present invention generally relates to methods and compositions to determine viability of an organ for transplantation and other medical purposes. One aspect of the invention relates to a method for assessing the viability of an organ by measuring the energy parameters to determine the energy level of the organ by determining the stored cellular energy (e.g., ATP levels), and/or energy consumption over a particular time period of viability. The energy parameters can be compared to reference energy parameters as a highly accurate and reliable prediction of viable cell yield, and organ viability. Another aspect of the invention relates methods to preserve or extend the time period of viability of an organ any combination of (i) preservation perfusion of the organ to prevent ischemic damage, (ii) chemical metabolic suppression of the organ e.g., using metabolic suppressants, (iii) metabolic suppression by physical or environmental conditions, e.g., sub-zero non-freezing storage. 198-. (canceled)100. The method of claim 99 , wherein determining a measure of viability comprises comparing a measured energy parameter to a threshold representative of a transplantability threshold of an organ and/or a threshold representative of a cell harvesting threshold of an organ.101. The method of claim 99 , further comprising storing the organ prior to assessing its viability.102. The method of claim 99 , further comprising implanting the organ in a subject.103. The method of claim 99 , further comprising harvesting the cells of the organ.104. The method of claim 99 , wherein measuring for at least one energy parameter comprises assaying for the level of ATP in the organ claim 99 , measuring cellular energy status claim 99 , measuring the cellular energy status during normothermic perfusion of the organ claim 99 , measuring the level of a plurality of metabolites claim 99 , measuring the oxygen consumption by the organ claim 99 , measuring the level of the gluconeogenesis of the ...

HEMATOLOGY CONTROL COMPOSITIONS WITH EXTENDED STABILITY

The present specification provides hematology control compositions having particular utility with a red blood cell component for devices using electronic and optical means for blood determinations, and methods for using the compositions. 114-. (canceled)15. A hematology control composition comprising a red blood cell component and an isotonic suspension medium including a serum albumin component and a cholesterol component , wherein the composition has a free fatty acid concentration of less than about 4 mmol/liter; and wherein the serum albumin component and the cholesterol component are present in amounts sufficient to provide a stable shelf life.16. The composition of claim 15 , wherein the serum albumin component and the cholesterol component are present in amounts sufficient to provide a shelf life of the composition of at least ninety-five days.17. The composition of claim 15 , wherein the shelf life of the composition is represented by a stabilization in mean cell volume claim 15 , a stabilization in red blood cell distribution width claim 15 , or both.18. The composition of claim 15 , wherein the red blood cell component is present in an amount sufficient to be measurable with an automated hematology instrument.19. The composition of claim 15 , wherein the serum albumin component is present at a concentration of from about 30 grams/liter to about 50 grams/liter.20. The composition of claim 15 , wherein the serum albumin component comprises a ratio of serum albumin monomer to serum albumin dimer lower than about 5:1.21. The composition of claim 15 , wherein the cholesterol component is present at a concentration of from about 400 mg/liter to about 1200 mg/liter.22. The composition of claim 15 , further comprising a nonionic surfactant component.23. The composition of claim 22 , wherein the nonionic surfactant component comprises a poloxamer.24. The composition of claim 15 , which further comprises a white blood cell component.25. The composition of claim 24 , ...

Organ Transplant Solutions and Methods for Transplanting Organs

A preservation solution for organs waiting to be transplanted is disclosed; the method of using the solution in a transplantation procedure is also disclosed. The preservation solutions comprise a balanced isotonic aqueous solution comprising sodium, potassium, calcium, magnesium and bicarbonate ions in a physiologically acceptable amount, together with an effective amount of a mutein of the C5a anaphylatoxin which is a C5a receptor antagonist wherein the amino acid residue naturally occurring at sequence position 69 is mutated. 120.-. (canceled)21. A method of preservation , storage and reperfusion of an organ intended for implantation , said method comprising perfusing said organ with a solution comprising:(a) a balanced isotonic solution comprising sodium, potassium, calcium, magnesium and bicarbonate ions in a physiologically acceptable amount;(b) a safe and effective amount of a mutein of the C5a anaphylatoxin which is a C5a receptor antagonist wherein the amino acid residue naturally occurring at sequence position 69 is mutated; and(c) water.22. The method of preservation according to wherein the C5a mutein is present at from about 0.1 to about 10 μM/liter of the solution.24. A method of preservation of organs intended for implantation claim 21 , said method comprising perfusing the body of the dead organ donor claim 21 , prior to removal of the organs claim 21 , with a solution comprising:(a) a balanced isotonic solution comprising sodium, potassium, calcium, magnesium and bicarbonate ions in a physiologically acceptable amount;(b) a safe and effective amount of a mutein of the C5a anaphylatoxin which is a C5a receptor antagonist wherein the amino acid residue naturally occurring at sequence position 69 is mutated; and(c) water.26. The method of preservation according to wherein the C5a mutein is present at from about 0.1 to about 10 μM/liter of the solution.27. The method of claim 21 , wherein claim 21 , in the mutein claim 21 , the amino acid residue at ...

TRANSPARENT COOLING GEL

For cooling organs and tissues in transplantation medicine, only ice preparations are used so far which are not soft like a gel and are brought to the necessary degree of comminution by mechanically comminuting frozen, sterile, pyrogen-free isotonic infusion solutions, such as 5% glucose or 0.9% saline, with great effort. The lack of gel-like consistency of the preparations and the expensive production process are very disadvantageous. 1. A method for cooling an organ before or during transplantation comprising directly contacting the organ with a cooling gel comprising 3% to 20% gelatin or gelatin derivative.2. The method of claim 1 , wherein the gel is sterile.3. The method of claim 1 , wherein the solution is sterile and pyrogen-free.4. The method of claim 1 , wherein the gelatin or the gelatin derivative is urea cross-linked gelatin claim 1 , oxypolygelatin or succinyl gelatin.5. The method of claim 1 , wherein the gelatin or the gelatin derivative is succinyl gelatin.6. The method of claim 1 , wherein the gelatin or the gelatin derivative has a mean molecular weight of 25-45 kD.7. The method of claim 1 , wherein the gel comprises 5%-15% claim 1 , gelatin or gelatin derivative.8. The method of claim 1 , wherein the gel comprises 6-20% gelatin or a gelatin derivative and physiologically acceptable electrolytes and has an osmolality of 280-650 mosmol/kg.9. The method of claim 1 , wherein the gel comprises 6-10% of gelatin or a gelatin derivative.10. The method of claim 1 , wherein the gel comprises 6%-9% claim 1 , gelatin or gelatin derivative.11. The method of claim 1 , wherein the gel comprises150-300 mmol/l sodium,5-10 mmol/l potassium,1.5-3 mmol/l magnesium,1.5-3 mmol/l calcium,100-200 mmol/l chloride, and30-60 mmol/l lactate.12. A method for producing a cooling gel comprising cooling a solution comprising 3%-20% of gelatin or a gelatin derivative to a temperature of below −1 ° C. until the aqueous solution becomes a mechanically stable claim 1 , formable gel. ...

Platelet Additive Solution Having a beta-Galactosidase Inhibitor

The present invention relates to a platelet additive solution (PAS) having an amount of one or more β-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PAS components that include a salt, a citrate source, a carbon source, or any combination thereof. 1. A platelet additive solution (PAS) , comprising:a. an amount of one or more β-galactosidase inhibitors and an amount of one or more sialidase inhibitors, and optionally an amount of one or more glycan-modifying agents; andb. one or more of PAS components that includes a salt, a citrate source, a carbon source, or any combination thereof.2. The PAS of claim 1 , wherein the PAS is maintained at a pH ranging between about 6.4 and about 7.6.3. The PAS of claim 1 , further including a phosphate source.4. The PAS of claim 2 , wherein the phosphate source is selected from the group consisting of sodium monophosphate claim 2 , sodium diphosphate claim 2 , sodium triphosphate claim 2 , and a combination thereof.5. The PAS of claim 1 , wherein the one or more PAS components include a citrate source claim 1 , and wherein the citrate source is selected from the group consisting of monosodium citrate claim 1 , disodium citrate claim 1 , trisodium citrate claim 1 , citric acid claim 1 , and a combination thereof.6. The PAS of claim 1 , wherein the one or more PAS components include a carbon source claim 1 , and wherein the carbon source is selected from the group consisting of acetate claim 1 , glucose claim 1 , and sucrose.7. The PAS of claim 6 , wherein the one or more PAS components include an acetate source claim 6 , and wherein the acetate source is selected from the group consisting of sodium acetate claim 6 , potassium acetate claim 6 , magnesium acetate claim 6 , and a combination thereof.8. The PAS of claim 1 , wherein the one or more PAS components include a salt claim 1 , and wherein the salt is selected from the ...

METHODS FOR THE PRESERVATION OF REAGENT RED BLOOD CELLS USING CARBON MONOXIDE

This application provides methods, compositions, and kits for use blood group determination and the preparation of improved red blood cell containing reagents for use in blood typing of blood prior to its use in transfusion medicine. 1. A method for preserving reagent red blood cells (RBC) comprising:a) obtaining packed red blood cells;b) flushing said packed red blood cells with a gas comprising carbon monoxide to prepare carbon monoxide saturated RBCs (CO-Hb RBCs); andc) storing said CO-Hb RBCs under anaerobic conditions in the presence of carbon monoxide (CO), wherein surface antigens of said CO-Hb RBCs are stabilized.2. The method of claim 1 , wherein said gas does not comprise oxygen.3. The method of claim 1 , wherein said CO-Hb RBCs are blood group O cells that are positive for the surface antigens selected from the group consisting of D claim 1 , C claim 1 , c claim 1 , E claim 1 , e claim 1 , CW claim 1 , K claim 1 , k claim 1 , P claim 1 , Fy claim 1 , Fy claim 1 , Jk claim 1 , Jk claim 1 , Le claim 1 , Le claim 1 , M claim 1 , N claim 1 , S claim 1 , and s.4. The method of claim 1 , wherein said CO-Hb RBCs are type-O cells that are negative for the surface antigens D claim 1 , C claim 1 , c claim 1 , E claim 1 , e claim 1 , f claim 1 , CW claim 1 , K claim 1 , k claim 1 , P claim 1 , Fy claim 1 , Fy claim 1 , Jk claim 1 , Jk claim 1 , Le claim 1 , Le claim 1 , N claim 1 , S claim 1 , s claim 1 , Lu claim 1 , and Lu.5. The method of claim 1 , wherein said CO-Hb RBCs are type-A cells that are positive for the surface antigen A2.6. The method of claim 1 , wherein said CO-Hb RBCs are type-B cells that are positive for the surface antigen B.7. The method of claim 1 , wherein said CO-Hb RBCs are type-O cells that{'sub': 1', '1, 'are positive for the surface antigens D, C, and e and having the Rh phenotype RR;'}{'sup': w', 'w, 'sub': 1', '1, 'are positive for the surface antigens D, C, and e and having the Rh phenotype RR;'}{'sub': 2', '2, 'are positive for the ...

HYDRATION MEDIA FOR BIOLOGICAL TISSUE PRODUCTS, METHODS OF MAKING THE SAME AND METHODS OF USING

A hydration media for biological tissue products, methods of making the same and methods of using the same is provided. The hydration media includes sodium phosphate and calcium silicate and can be used to store or hydrate a biological tissue product. 1. A hydration medium for hydrating or storing at least one biological tissue , comprising: a sodium phosphate;', 'a calcium silicate; and', 'water, wherein the hydration media comprises an osmolality of about 200-about 400 milliosmoles per kilogram., 'a solution comprising2. The hydration medium of claim 1 , wherein the calcium silicate component is present at a concentration of about 0.025-about 0.100 milligrams per milliliter.3. The hydration medium of claim 1 , further comprising at least one of a potassium claim 1 , a chloride claim 1 , and a magnesium.4. The hydration medium of claim 1 , wherein a pH of the hydration media is between 7.0 and 7.7.5. The hydration medium of claim 1 , further comprising at least one additional solvent comprising an ethanol claim 1 , a dimethylsulfoxide claim 1 , or a glycerol.6. The hydration medium of claim 1 , wherein the at least one biological tissue is selected from the group comprising an allogeneic claim 1 , an autogeneic claim 1 , a xenogeneic claim 1 , and combinations thereof.7. The hydration medium of claim 1 , wherein the at least one biological tissue is selected from the group consisting of a bone claim 1 , a connective tissue claim 1 , a tendon claim 1 , a pericardium claim 1 , a dermis claim 1 , a cornea claim 1 , a dura mater claim 1 , a fascia claim 1 , a heart valve claim 1 , a ligament claim 1 , a capsular graft claim 1 , a cartilage claim 1 , a collagen claim 1 , a nerve claim 1 , a placental tissue claim 1 , and combinations thereof.8. The hydration medium for biological tissue of claim 7 , wherein the biological tissue is the bone.9. The hydration medium of claim 8 , wherein the bone is selected from the group consisting of a cortical bone claim 8 , a ...

Platelet Protection Solution Having Beta-Galactosidase and Sialidase Inhibitors

The present invention relates to a platelet protection solution (PPS) having an amount of one or more β-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of PPS components that include a salt, a citrate source, a carbon source, or any combination thereof. 1. A platelet protection solution (PPS) , comprising:a. an amount of one or more β-galactosidase inhibitors and an amount of one or more sialidase inhibitors, and optionally an amount of one or more glycan-modifying agents;b. PPS components in a form of salt, consisting essentially of:a sodium source in an amount ranging between about 100 mM and about 300 mM;a chloride source in an amount ranging between about 40 mM and about 110 mM;an acetate source in an amount ranging between about 10 mM and about 50 mM;a phosphate source in an amount ranging between about 5 mM and about 50 mM;a potassium source in an amount ranging between about 0.5 mM and about 10 mM; anda magnesium source in an amount ranging between about 0.5 mM and about 5.0 mM.2. The PPS of claim 1 , further comprising at least one of the group consisting of:a. a calcium source in an amount ranging between about 0.1 mM and about 2.5 mM;b. a glucose source in an amount ranging between about 0.1 mM and about 30 mM;c. a citrate source in an amount ranging between about 2 mM and about 20 mM; andd. a combination thereof.3. The PPS of claim 1 , wherein the chloride source is present in the amount ranging between about 90 mM and about 110 mM;4. The PPS of claim 1 , wherein the PPS is maintained at a pH ranging between about 6.4 and about 7.6.5. The PPS of claim 1 , wherein the phosphate source is selected from the group consisting of sodium monophosphate claim 1 , sodium diphosphate claim 1 , sodium triphosphate claim 1 , and a combination thereof.6. The PPS of claim 2 , wherein the citrate source is selected from the group consisting of monosodium citrate ...

MULTILAYER INSULATION OF BIOLOGICAL SAMPLES AND COOLING BY IMMERSING IN A CRYOGENIC LIQUID FOR CRYOPRESERVATION

A container system and method for cryopreservation of sperm includes first containers having walls of a desired thickness and thermal conductivity. At least one layer of thermally insulating walls of a desired thickness and thermal conductivity is disposed around the at least one row of first containers. The first containers and thermally insulating walls are capable of being immersed from a range of about 5° C. to room temperature directly into a liquid cryogenic fluid below a surface thereof and freezing the sperm, without vitrification, at a cooling rate sufficient to maintain post-thaw quality of the sperm. The cooling rate is controlled solely by the thermal conductivity of the walls of the first containers, the layer(s) of thermally insulating walls and any substance between the walls of the first containers and the at least one thermally insulating container. 1. A method of cryopreservation of sperm comprising:providing a liquid suspension of sperm to be frozen;placing the liquid suspension of sperm in one or more first containers having walls of a desired thickness and thermal conductivity;placing the one or more first containers in at least one insulating container having thermally insulating walls of a desired thickness and thermal conductivity, the first containers being arranged within the at least one thermally insulating container;providing a liquid cryogenic fluid;immersing the at least one thermally insulating container with the first containers containing liquid suspension of sperm from range of about 5° C. to room temperature directly into the liquid cryogenic fluid, the first containers being below a surface thereof; andfreezing the sperm, without vitrification, at a cooling rate sufficient to maintain post-thaw quality of the sperm, the cooling rate being controlled solely by the thermal conductivity of the walls of the one or more first containers, the walls of the at least one thermally insulating container and any substance between the walls ...

DEVICES AND METHODS TO IMPROVE AND ASSESS VIABILITY OF HUMAN LIVERS

The present invention relates to organ perfusion systems that can be used at room temperature. The organ perfusion systems do not comprise a temperature controller. In some embodiments, the organ perfusion systems do not comprise a cleaning device for cleaning the perfusion fluid. The perfusion fluid can comprise Williams' medium E. The organ perfusion systems can be portable and can be used to preserving an organ, preventing ischemic damage in an organ, or recovering an ischemically damaged organ. 1. An organ perfusion system operating at room temperature , the system comprisinga first container configured to encase an organ removed from a subject and store a perfusion fluid, whereby the organ is at least partially immersed in the perfusion fluid;a fluidic circuit system having a first end connected to the perfusion fluid stored in the first container and a second end connected to the organ, the fluidic circuit system configured to draw the perfusion fluid through the first end and perfuse the organ with the perfusion fluid, and wherein the organ perfusion system does not comprise a temperature controller.2. The organ perfusion system of claim 1 , wherein the organ perfusion system does not comprise a cleaning device for cleaning the perfusion fluid.3. (canceled)4. The organ perfusion system of claim 1 , wherein the organ perfusion system is portable.5. The organ perfusion system of claim 1 , wherein the fluidic circuit system comprises a pressure sensor configured to measure the pressure of the perfusion fluid flowing towards the organ.6. The organ perfusion system of claim 1 , wherein the fluidic circuit system comprises a pump configured to control the pressure of the perfusion fluid as a function of the measurements of the pressure sensor.7. The organ perfusion system of claim 1 , wherein the fluidic circuit system comprises an oxygenator configured to increase oxygen level in the perfusion fluid flowing towards the organ.8. The organ perfusion system of claim ...

Methods, systems and apparatus for preservation of organs and other aqueous-based materials utilizing low temperature and elevated pressure

This invention uses low temperature and elevated pressure to induce suspended animation by depressing the freezing and melting temperature of water and aqueous solutions, including but not limited to biological materials, soluble molecules, organic and inorganic compounds. Increasing the pressure to ˜210 MPa in a container depresses the freezing and melting temperature of water, biological matter, and materials in aqueous solution, to ˜−22° C. Storage at low temperature under high pressure suspends metabolic activity and induces cryostasis. This invention can be used for cryo-banking biological materials that cannot be frozen or vitrified, or otherwise preserved, including, but not limited to, cells, tissues, human organs for transplantation or entire organisms. 1. A method for storing/preservation , including but not limited to , water , organic and inorganic aqueous-based materials/substances/media , materials in aqueous suspension , aqueous solutions , aqueous mixtures , aqueous colloids , aqueous-based materials , biological materials , biologics , and materials of biological origin at temperatures below their freezing , i.e. melting , temperature at ambient pressure by means of increased pressure. Increasing the pressure applied to any or all of the above materials , in a container , depresses their freezing , i.e. melting temperature (point). The temperature range for storage where it is not possible for the above substances to freeze or vitrify extends from −0.001° C. to −21.985° C. The melting point , i.e. freezing point , of the above materials being depressed by pressure over the pressure range from ambient pressure to 209.9 MPa. These biological materials are , but not limited to , organic molecules and molecular complexes , nucleic acids , saccharides , amino acids , peptides , proteins , enzymes , organelles , cells , tissues , organs , and organisms.2. A method of storing aqueous-based material under pressure to prevent phase transition to solid and ...

Modulating Ischemic Injury

The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents. 120.-. (canceled)21. A method for modulating ischemic injury in an ischemic lung , the method comprising the step of administrating a composition comprising Amnion-derived Cellular Cytokine Solution (ACCS) to the ischemic lung such that the ischemic injury is modulated , wherein the ACCS is formulated for spray administration.22. The method of wherein the ACCS is further formulated for sustained-release claim 21 , targeted-release claim 21 , timed-release claim 21 , or extended-release.23. A method for reducing ischemic injury in an ischemic lung claim 21 , the method comprising the step of administrating a composition comprising ACCS to the ischemic lung such that the ischemic injury is reduced claim 21 , wherein the ACCS is formulated for spray administration.24. The method of wherein the ACCS is further formulated for sustained-release claim 23 , targeted-release claim 23 , timed-release claim 23 , or extended-release.25. A method for increasing the time to ischemic injury in a lung at risk for developing ischemic injury claim 23 , the method comprising the step of administrating a composition comprising ACCS to the ischemic lung such that the time to ischemic injury is increased claim 23 , wherein the ACCS is formulated for spray administration.26. The method of wherein the ACCS is further formulated for ...

DECELLULARIZED TISSUE PRODUCING METHOD AND DECELLULARIZED TISSUE PRODUCING APPARATUS

A decellularized tissue producing method includes degrading DNA included in a biological tissue in which cells are destroyed, by using a first treatment liquid; degreasing the biological tissue in which the DNA is degraded, by using a second treatment liquid; and washing the degreased biological tissue, by using a third treatment liquid. At least one of the degrading, the degreasing, and the washing is performed by a circulation method. 1. A decellularized tissue producing method comprising:degrading DNA included in a biological tissue in which cells are destroyed, by using a first treatment liquid;degreasing the biological tissue in which the DNA is degraded, by using a second treatment liquid; andwashing the degreased biological tissue, by using a third treatment liquid, whereinat least one of the degrading, the degreasing, and the washing is performed by a circulation method.2. The decellularized tissue producing method according to claim 1 , wherein the first treatment liquid is a liquid including an enzyme or a surfactant.3. The decellularized tissue producing method according to claim 1 , wherein the second treatment liquid is a liquid including an organic solvent.4. The decellularized tissue producing method according to claim 3 , wherein the organic solvent is ethanol.5. The decellularized tissue producing method according to claim 1 , wherein the third treatment liquid includes water as a main solvent.6. The decellularized tissue producing method according to claim 1 , further comprising:destroying the cells in the biological tissue by using a liquid including liquefied gas, whereinthe destroying is performed under a predetermined condition in which the liquefied gas is maintained in a liquid state.7. The decellularized tissue producing method according to claim 6 , wherein the liquefied gas is liquefied dimethyl ether.8. The decellularized tissue producing method according to claim 7 , wherein the predetermined condition is a condition of a temperature of ...

METHOD AND SYSTEM FOR RECOVERY OF LIVING CELLS FROM CRYOPRESERVED CELLS

A method is disclosed for recovering living cells highly efficiently from cryopreserved cells by thawing and a system designed for such a method. The method for recovering living cells from cryopreserved cells includes thawing cryopreserved cells and diluting the thawed cell suspension with a diluent, wherein the dilution is performed in such a way that the maximum load of osmotic pressure at the time of dilution is equal to or less than 250 mOsm/second. 1. A method for recovering living cells from cryopreserved cells , comprisingthawing cryopreserved cells;diluting the thawed cell suspension with a diluent; andperforming the dilution such that a maximum load of osmotic pressure at the time of dilution is equal to or less than 250 mOsm/second.2. The method according to claim 1 , comprising:adding the diluent such that the maximum load of osmotic pressure at the time of dilution is equal to or less than 50 mOsm/second.3. The method according to claim 1 , comprising:adding the diluent such that the maximum load of osmotic pressure at the time of dilution ranges from 40 mOsm/second to 50 mOsm/second.4. The method according to claim 1 , wherein the cells are skeletal muscle blast cells.5. The method according to claim 1 , wherein the diluent contains rinsing liquid resulting from rinsing of a container for cryopreservation from which the thawed cell suspension has been transferred to another container.6. A system for thawing cryopreserved cells claim 1 , comprising:an actuating unit configured to inject a diluent; andan arithmetic control unit configured to determine the rate at which the actuating unit injects the diluent.7. The system according to claim 6 , further comprising a measuring unit configured to measure osmotic pressure of liquid.8. The system according to claim 6 , wherein a maximum load of osmotic pressure at a time of dilution is equal to or less than 250 mOsm/second.9. The system according to claim 7 , wherein the maximum load of osmotic pressure at the ...

ACELLULAR COLLAGENOUS TISSUE AND A PROCESSING METHOD OF ARTIFICIAL HEART VALVE COMPRISING THE ACELLULAR COLLAGENOUS TISSUE

The present invention provides an acellular collagenous tissue and a method for processing an artificial heart valve containing the acellular collagenous tissue. The method comprises immersing the acellular collagenous tissue in a preservation liquid containing an ionic liquid until the size of the acellular collagenous tissue remains stable in a non-liquid environment. The present invention also provides a preservation method, comprising immersing the acellular collagenous tissue or the artificial heart valve containing acellular collagenous tissue in the preservation liquid containing ionic liquid until the size of the collagen tissue remains stable in the non-liquid environment. The present invention also provides an acellular collagenous tissue and an artificial heart valve containing the acellular collagenous tissue processed by the method described above. The method can effectively avoid a biological material damage caused by being in a non-liquid environment and is beneficial to implement a subsequent processing and sterilization for the biological material. 1. A method for preservation processing an acellular collagenous tissue , comprising immersing the acellular collagenous tissue in a preservation liquid containing an ionic liquid until size of the acellular collagenous tissue remains stable in a non-liquid environment.2. The method according to claim 1 , wherein the preservation liquid also contains one or more substances of water claim 1 , water-soluble alcohols claim 1 , water-soluble carbohydrates and water-soluble rubber.3. The method according to claim 1 , wherein the preservation liquid contains at least 10% volume fraction of the ionic liquid.4. The method according to claim 1 , wherein the ionic liquid is miscible with water.5. The method according to claim 1 , wherein the ionic liquid is biocompatible.6. The method according to claim 1 , wherein the ionic liquid is one or a combination of two or more of quaternary ammonium salt ionic liquids and ...

EX VIVO ORGAN TREATMENT WITH PEG-PHOSPHOLIPID MOLECULES

An organ graft is ex vivo treated by ex vivo infusing a solution comprising PEG-phospholipid molecules into a vascular system of the organ graft. The solution comprising PEG-phospholipid molecules is ex vivo incubated in the vascular system to enable coating of at least a portion of the endothelial lining of the vascular system with the PEG-phospholipid molecules while keeping the organ or the part of the organ submerged in an organ preservation solution comprising PEG-phospholipid molecules. Such an ex vivo treatment of organ grafts with PEG-phospholipid protected the organ grafts against thromboinflammation and reduced blood pressure drops that otherwise occurred when reperfusing the organ graft in the recipient. 116.-. (canceled)17. An ex vivo method of treating an organ or a part of the organ , the method comprising:ex vivo infusing a solution comprising poly(ethylene glycol)-phospholipid (PEG-phospholipid) molecules into a vascular system of the organ or the part of the organ; andex vivo incubating the solution comprising PEG-phospholipid molecules in the vascular system to enable coating of at least a portion of the endothelial lining of the vascular system with the PEG-phospholipid molecules while keeping the organ or the part of the organ submerged in an organ preservation solution comprising PEG-phospholipid molecules.18. The method according to claim 17 , further comprising:ex vivo infusing an organ preservation solution into the vascular system to flush away non-bound PEG-phospholipid molecules from the vascular system.19. The method according to claim 17 , further comprising:ex vivo infusing an organ preservation solution into the vascular system prior to ex vivo infusing the solution comprising PEG-phospholipid molecules into the vascular system.20. The method according to claim 17 , wherein ex vivo infusing the solution comprises:ex vivo clamping one of an artery and a vein of the vascular system;ex vivo infusing the solution comprising PEG- ...

MODULATING ISCHEMIC INJURY

The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents. 1. A method for modulating ischemic injury in tissues or organs , the method comprising the step of perfusing and/or immersing the tissue or organ with a composition comprising Amnion-derived Cellular Cytokine Solution (ACCS).2. The method of wherein the ACCS is formulated for sustained-release claim 1 , targeted-release claim 1 , timed-release claim 1 , or extended-release.3. The method of wherein the tissue or organ is a donated tissue or organ intended for transplant.4. The method of wherein the tissue is selected from the group consisting of epithelial tissue claim 1 , connective tissue claim 1 , muscle tissue and nervous tissue.5. The method of wherein the organ is selected from the group consisting of heart claim 1 , blood vessel claim 1 , alimentary canal claim 1 , stomach claim 1 , liver claim 1 , pancreas claim 1 , spleen claim 1 , kidney claim 1 , lung claim 1 , trachea claim 1 , cornea claim 1 , lens claim 1 , eye claim 1 , bladder claim 1 , ureter claim 1 , urethra claim 1 , uterus claim 1 , ovary claim 1 , testis claim 1 , nerve claim 1 , skin claim 1 , tooth claim 1 , and skeletal muscle.6. A method for reducing ischemic injury in tissues or organs claim 1 , the method comprising the step of perfusing and/or immersing the tissue or organ with a composition comprising ACCS.7. The method of wherein the ...

USES OF OXYGENATED CHOLESTEROL SULFATES (OCS)

Methods of preventing and/or treating ischemia, organ dysfunction and/or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction/failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted). 1. A method of prophylactically treating or treating ischemia caused by surgery in a subject in need thereof , comprisingadministering to the subject an amount of 5-cholesten-3,25-diol, 3-sulfate (25HC3S) that is sufficient to prophylactically treat or treat ischemia.2. The method of claim 1 , wherein the ischemia comprises at least one member selected from cardiac ischemia claim 1 , brain ischemia claim 1 , bowel ischemia claim 1 , limb ischemia claim 1 , and cutaneous ischemia.3. The method of claim 1 , wherein the prophylactically treating or treating ischemia comprises reducing one or more of inflammation claim 1 , tissue necrosis claim 1 , organ necrosis claim 1 , risk of stroke claim 1 , and reperfusion injury in the subject.4. The method of claim 1 , wherein the surgery comprises at least one of cardiovascular surgery claim 1 , heart surgery claim 1 , and aneurysm surgery.5. The method of claim 1 , wherein the 25HC3S is administered for not more than seven days prior to the surgery.6. The method of claim 1 , wherein the 25HC3S is administered during the surgery.7. The method of claim 1 , wherein the 25HC3S is administered for not more than seven days after the surgery.8. The method of claim 1 , wherein the surgery is not liver surgery.9. The method of claim 1 , wherein the surgery is not a transplant surgery.11. The method of claim 10 , wherein the one or more organs comprises at least one member selected from the liver claim ...

SYSTEM FOR HYPOTHERMIC TRANSPORT OF SAMPLES

A system for the hypothermic transport of biological samples, such as tissues, organs, or body fluids. The system includes a self-purging preservation apparatus to suspend a sample in preservation fluid and perfuse a tissue with preservation fluid. The self-purging preservation apparatus is placed in an insulated transport container having a cooling medium. When assembled, the system allows for transport of biological samples for extended periods of time at a stable temperature. 119-. (canceled)20. A method of preserving a biological sample , comprising:introducing a biological sample to a transport container, wherein the transport container comprises:a pumping chamber having a semi-permeable membrane configured to push against a preservation fluid and cause the preservation fluid to circulate inside the transport container;a sample storage chamber, configured to receive the biological sample, and configured to interface with and be in fluidic communication with the pumping chamber;a fill port providing a fluid path between the exterior of the transport container and the sample storage chamber; anda vent port providing a fluid path between the exterior of the transport container and the pumping chamber; andfilling the sample storage chamber and the pumping chamber through the fill port with the preservation fluid.21. The method of claim 20 , wherein filling comprises allowing preservation fluid to exit the transport container from the vent port.22. The method of claim 20 , wherein the preservation solution comprises glucose claim 20 , histidine claim 20 , lactobionate claim 20 , mannitol claim 20 , raffinose claim 20 , or sucrose.23. The method of claim 20 , wherein the preservation solution is selected from the group consisting of Collins claim 20 , EuroCollins claim 20 , phosphate buffered sucrose (PBS) claim 20 , University of Wisconsin (UW) claim 20 , histidine-tryptophan-ketoglutarate (HTK) claim 20 , hypertonic citrate claim 20 , hydroxyethyl starch claim 20 , ...

URINE PRESERVATIVE REAGENT FOR MICROFILTRATION

A preservative reagent for urine is disclosed that increases the stability of cells, such as tumor cells, in urine for a period of several weeks. The preservative reagent comprises polyethylene glycol (PEG), ethanol, paraformaldehyde (PFA), and ethylenediaminetetraacetic acid (EDTA), and optionally pH stabilizing reagents. 1. A preservative reagent comprising 0.2-20% PEG , 25-75% ethanol , 0.04-4% PFA , and 2-200 mM EDTA.2. The preservative reagent of claim 1 , further comprising one or more pH stabilizing reagents.3. The preservative reagent of claim 2 , wherein the pH of the reagent is in a range of pH 4.0-10.0 claim 2 , more preferably in a range of 7.3-7.5 claim 2 , and preferably at pH 7.4.4. A preservative reagent comprising 0.5-5% PEG claim 2 , 40-60% ethanol claim 2 , 0.01-2% PFA claim 2 , and 5-50 mM EDTA.5. The preservative reagent of claim 4 , further comprising one or more pH stabilizing reagents.6. The preservative reagent of claim 5 , wherein the pH of the reagent is in a range of pH 4.0-10.0 claim 5 , more preferably in a range of 7.3-7.5 claim 5 , and preferably at pH 7.4.7. A preservative reagent comprising 2% PEG-1450 claim 5 , 50% ethanol claim 5 , 0.4% PFA claim 5 , and 20 mM EDTA.8. The preservative reagent of claim 7 , further comprising one or more pH stabilizing reagents.9. The preservative reagent of claim 8 , wherein the pH of the reagent is in a range of pH 4.0-10.0 claim 8 , more preferably in a range of 7.3-7.5 claim 8 , and preferably at pH 7.4.10. A method for preparing a preserved urine sample comprising adding a preservative reagent of to urine claim 1 , wherein the ratio of the preservative reagent to urine in the sample is from about 0.1:20 to about 10:0.2 (vol:vol).11. The method of claim 10 , wherein the ratio of the preservative reagent to urine in the sample is from about 0.5:4 to about 2:1 (vol:vol).12. The method of claim 10 , wherein the ratio of the preservative reagent to urine in the sample is about 1:2 (vol:vol).13. A ...

MODULATION OF CALCIUM ION HOMEOSTASIS IN HARVESTED TRANSPLANTABLE HEARTS

An oxygenated cardioplegic composition for immediate reperfusion of a donor heart after its procurement. The composition comprises an adenosine-lidocaine mixture for causing immediate cessation of the heart's systolic function upon contact; a normokalemic concentration of potassium ions; a concentration of Ca ions selected to maintain the intracellular level of Ca ions in the harvested heart muscle cells at about 10mmol/L; and a pH of 6.9. The oxygenated cardioplegic composition is pre-warmed to about 35° C. and then used for immediate reperfusion of a donor heart for at least three minutes after its procurement. 1. A cardioplegic composition for reperfusion of a procured donor heart , comprising:an adenosine-lidocaine mixture for causing immediate cessation of the heart's systolic function upon contact;a normokalemic concentration of potassium ions;{'sup': 2+', '2+', '−4, "a concentration of Ca ions selected to maintain an intracellular level of Ca ions in the procured donor heart's muscle cells at about 10mmol/L; and"}a pH of 6.9.2. A cardioplegic composition according to claim 1 , comprising:300 μmol/L to 450 μmol/L of adenosine;40 μmol/L to 90 μmol/L of lidocaine;8.0 mmol/L to 12.5 mmol/L of glucose;120 mmol/L to 140 mmol/L of NaCl4.0 mmol/L to 7.0 mmol/L of KCL;{'sub': '3', '12.0 mmol/L to 16.0 mmol/L of NaHCO;'}{'sub': 2', '4, '0.9 mmol/L to 1.4 mmol/L of NaHPO;'}{'sub': '2', '0.18 mmol/L to 0.26 mmol/L of CaCl;'}{'sub': '2', '11.0 mmol/L to 15.0 mmol/L of MgCl;'}7.5 IU/L to 12.5 IU/L of insulin;100.0 mmol/L to 140.0 mmol/L of D-mannitol;0.75 mmol/L to 1.25 mmol/L of pyruvate; and2.5 mmol/L to 3.5 mmol/L of reduced glutathione.3. A cardioplegic composition according to claim 1 , comprising:400 μmol/L of adenosine;50 μmol/L of lidocaine;10.0 mmol/L of glucose;131.8 mmol/L of NaCl;5.9 mmol/L of KCL;{'sub': '3', '14.0 mmol/L of NaHCO;'}{'sub': '4', '1.2 mmol/L of NaH2PO;'}{'sub': '2', '0.22 mmol/L of CaCl;'}{'sub': '2', '13.0 mmol/L of MgCl;'}10.0 IU/L of ...

PLATELET STORAGE METHODS AND COMPOSITIONS FOR SAME

Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier. 132.-. (canceled)34. The method of claim 33 , wherein said RHOA inhibitor is present at a concentration of from about 1 μM to about 500 μM.35. The method of claim 33 , wherein the platelets are stored in the presence of the RHOA inhibitor at a temperature of from about 1° C. to about 25° C.36. The method of claim 33 , wherein the platelets are stored in the presence of the RHOA inhibitor for a period of time of from about 3 to 20 days.37. The method of claim 33 , wherein the platelets are further contacted with a physiologically acceptable carrier.38. The method of claim 37 , wherein said physiologically acceptable carrier is selected from saline claim 37 , phosphate buffered saline claim 37 , Tris buffered saline claim 37 , Hank's buffered saline claim 37 , water claim 37 , or a combination thereof.39. The method according to claim 37 , wherein said physiologically acceptable carrier comprises an electrolyte solution.41. The method of claim 40 , wherein said RHOA inhibitor is present at a concentration of from about 1 μM to about 500 μM.42. The method of claim 40 , wherein the platelets are stored in the presence of the RHOA inhibitor at a temperature of from about 1° C. to about 25° C.43. The method of claim 40 , wherein the platelets are stored in the presence of the RHOA inhibitor for a period of time of from about 3 to 20 days.44. The method of claim 40 , wherein wherein claim 40 , prior to said infusing claim 40 , the platelets have further been contacted with a physiologically acceptable carrier.45. The method of claim 44 , wherein said physiologically acceptable carrier is selected from ...

NOVEL COMPOSITION AND SOLUTION WITH CONTROLLED CALCIUM ION LEVEL, AND RELATED METHOD AND USE FOR REPERFUSION

A solution comprises a preservation mixture comprising a calcium ion source; and a buffer for maintaining a pH of the solution. The molar concentration of calcium ion (Ca) in the solution is from 0.18 to 0.26 mmol/L, and the pH is lower than 7.4 and higher than 6.6. A composition for preparing the solution may comprise adenosine, lidocaine, and a calcium source, wherein the molar ratio of adenosine:calcium is from 0.3:0.26 to 0.45:0.18, and the molar ratio of lidocaine:calcium is from 0.04:0.26 to 0.09:0.18. A donor heart may be reperfused with the solution. The solution may be used for reperfusion of a donor heart, such as at a temperature from about 25 to about 37° C. The donor may be a donor after circulatory death. 1. A composition for preparing a solution , the composition comprising:adenosine;lidocaine; anda calcium source,wherein the molar ratio of adenosine:calcium in the composition is from 0.3:0.26 to 0.45:0.18, and the molar ratio of lidocaine:calcium in the composition is from 0.04:0.26 to 0.09:0.18,{'sup': '2+', 'wherein the solution comprises a cardioplegia mixture and a buffer for maintaining a pH of the solution, the cardioplegia mixture comprises 0.3 to 0.45 mmol/L of adenosine, 0.04 to 0.09 mmol/L of lidocaine, and 0.18 to 0.26 mmol/L of calcium ion (Ca), and the pH is lower than 7.4 and higher than 6.6.'}2. The composition of claim 1 , wherein the molar ratio of adenosine:calcium is 0.4:0.22 claim 1 , and the molar ratio of lidocaine:calcium is 0.05:0.22.3. The composition of claim 1 , further comprising a sodium source claim 1 , a potassium source and a magnesium source claim 1 , wherein the molar ratio of calcium:sodium is from 0.26:130 to 0.18:160 claim 1 , the molar ratio of calcium:potassium is from 0.26:4 to 0.18 to 7 claim 1 , and the molar ratio of calcium:magnesium is from 0.26:11 to 0.18:15.4. The composition of claim 1 , wherein the molar concentration of calcium ion (Ca) in the solution is 0.22 mmol/L.5. The composition of claim 1 , ...

CELLULAR CULTURE MEDIUM FREE FROM SERUM

The present invention relates to a cell culture medium, in particular for culturing autologous fibroblasts, for use in aesthetic medicine for skin transplantation, said culture medium being serum-free and being characterized in that it contains glucose in a much lower quantity than conventional culture media. 19-. (canceled)10. A method for improving biomechanical properties of skin comprising transplanting to a subject in need thereof a cell culture of fibroblasts expanded in a saline aqueous solution consisting of:a mixture of biologically acceptable mineral salts consisting of sodium chloride, potassium chloride, sodium bicarbonate, sodium dihydrogen phosphate, magnesium chloride and calcium chloride,D-glucose,Vitamin B6 and vitamin C, andwater;wherein in the saline aqueous solution glucose is in a concentration<6 mM, vitamin C is in a concentration of between 0.05 mM and 2 mM and vitamin B6 is in a concentration of between 5 mM and 20 mM.11. The method of claim 10 , wherein in the saline aqueous solution the concentration of glucose is 5.5 mM. The present invention relates to a cell culture medium, especially for culturing human autologous fibroblasts intended for skin transplantation into the field of aesthetics or regenerative medicine.In aesthetic and regenerative medicine, the use of autologous fibroblasts transplantation, in jargon also called “Autotransplantation”, is a technique employed for quite some time.With aging, the number of active fibroblasts in the skin tends to decrease, as well as the metabolic capabilities thereof. The increase of cells due to transplantation of autologous fibroblasts with the ability to synthesize the extracellular matrix allows for counteracting the effects of skin aging.Indeed, it was clinically demonstrated that, in patients who were injected with cultures of autologous fibroblasts from explants of the same patients and cultivated in vitro, they have improved the biomechanical properties of skin of above-mentioned ...

METHODS FOR INDUCING IMMUNE TOLERANCE TO ORGAN TRANSPLANTS

The present invention is directed to methods of treating an organ or a tissue prior to transplantation thereof into a recipient, comprising ablating the cells composing the blood vessels of said organ or tissue, preferably the cells lining the lumen surface of the blood vessels, thereby obtaining a treated viable organ or tissue having reduced immunogenicity. The invention is also directed to treated viable organs or tissues having reduced immunogenicity and uses thereof. 132-. (canceled)33. A method of treating an organ or a tissue prior to transplantation thereof into a recipient , comprising:(a) providing an organ or a tissue intended for transplantation; and(b) ablating the cells composing the blood vessels of said organ or tissue; thereby obtaining a treated viable organ or tissue having reduced immunogenicity.34. The method of wherein step (b) comprises:(a) ablating the cells of the tunica intima cell layer lining the lumenal surface of the blood vessels of said organ or tissue; or(b) ablating the cells composing the tunica intima cell layer and the tunica media cell layer of the blood vessels of said organ or tissue; or(c) ablating the cells composing the tunica intima cell layer, the tunica media cell layer and the tunica adventitia cell layer of the blood vessels of said organ or tissue.35. The method of wherein said step of ablating the cells comprises subjecting said organ or transplant to at least one cycle of perfusion with an ablating substance solution comprising at least one substance capable of destroying or neutralizing said cells.36. The method of wherein said at least one substance is selected from a group consisting of a solubilizing agent claim 35 , a detergent claim 35 , a chelating agent claim 35 , an enzyme claim 35 , an antibody claim 35 , a hypertonic solution claim 35 , a hypotonic solution claim 35 , a dehydrating agent claim 35 , and any combination thereof.37. The method of claim 35 , wherein said perfusion is performed for a duration ...

Allografts Combined with Tissue Derived Stem Cells For Bone Healing

There is disclosed a method of combining mesenchymal stem cells (MSCs) with a bone substrate. In an embodiment, the method includes obtaining tissue having MSCs together with unwanted cells. The tissue is digested to form a cell suspension having MSCs and unwanted cells. The cell suspension is added to the substrate. The substrate is cultured to allow the MSCs to adhere. The substrate is rinsed to remove unwanted cells. In various embodiments, the tissue is adipose tissue, muscle tissue, or bone marrow tissue. In an embodiment, there is disclosed an allograft product including a combination of MSCs with a bone substrate in which the combination is manufactured by culturing MSCs disposed on the substrate for a period of time to allow the MSCs to adhere to the substrate, and then rinsing the substrate to remove unwanted cells from the substrate. Other embodiments are also disclosed. 163-. (canceled)64. A method of making an allograft product for enhancing bone formation , the method consisting of:providing a bone substrate obtained from a human, cadaveric donor;providing an adipose stromal vascular fraction obtained from the human, cadaveric donor, the adipose stromal vascular fraction comprising mesenchymal stem cells and unwanted cells;adding the stromal vascular fraction to the bone substrate to form a seeded bone substrate;incubating the seeded bone substrate for a period of time to allow the mesenchymal stem cells to adhere to the bone substrate; andrinsing the seeded bone substrate to remove the unwanted cells from the bone substrate;thereby making the allograft product for enhancing bone formation, wherein the allograft product comprises bone substrate with mesenchymal stem cells adhered thereto.65. A method in accordance with claim 64 , wherein the adipose stromal vascular fraction is prepared by enzymatically digesting the adipose tissue to form digested adipose tissue.66. A method in accordance with claim 65 , further comprising centrifuging the digested ...

PRESERVATION OF BIOMATERIAL PROPERTIES AND METHODS OF STORING

Described herein are enhanced compositions and methods for storing biomaterials. In certain aspects, these biomaterials include natural and engineered eukaryotic tissues. The methods described herein include storing these biomaterials in such a manner that reduces or prevents the loss of biomaterial properties (e.g., extracellular matrix integrity, cell viability, or a combination thereof) occurring either during storage or after removal of the biomaterial from storage. In certain aspects, these biomaterials will be stored in animal product-free solutions containing an agent that prevents or reduces the loss of extracellular matrix integrity. 1. A composition comprising a biomaterial placed in a solution that includes at least one agent that reduces or prevents a loss of biomaterial properties , whereinthe solution is an animal product-free solution,the biomaterial comprises chondrocytes in an extracellular matrix or cartilage, andthe at least one agent comprises an enzyme inhibitor of a matrix metalloproteinase having a concentration ranging from 1.0 nM to 1 mM.2. The composition of claim 1 , wherein the biomaterial properties comprise extracellular matrix integrity claim 1 , cell viability claim 1 , or a combination thereof.3. The composition of claim 2 , wherein extracellular matrix integrity comprises extracellular matrix permeability claim 2 , extracellular matrix water content claim 2 , extracellular matrix glycosaminoglycan content claim 2 , or any combination thereof.4. The composition of claim 1 , wherein the biomaterial comprises cartilage.5. The composition of claim 1 , wherein the biomaterial comprises chondrocytes in an extracellular matrix.6. The composition of claim 1 , wherein the solution does not include fetal bovine serum.7. The composition of claim 1 , wherein the animal product-free solution is an extracellular-type solution that is isotonic.8. The composition of claim 1 , wherein the animal product-free solution is an intracellular-type ...

ORGAN-PRESERVING COMPOSITION AND USES

The invention relates to the use of a composition comprising at least one globin, one globin protomer or one extracellular hemoglobin of Annelida, a stabilizing solution and/or a solution for conserving organs, said composition having a temperature of between 0° C. and 37° C., for preserving an organ in a donation after brain death donor or a donation after cardiac death donor. 1. The use of a composition comprising at least one globin , one globin protomer or one extracellular hemoglobin of annelids , a stabilizing solution and/or an organ preservation solution , said composition having a temperature of between 0° C. and 37° C. , for preserving an organ in a donation after brain death donor or a donation after cardiac death donor.2. The use as claimed in claim 1 , wherein the extracellular hemoglobin of annelids is chosen from the extracellular hemoglobins of polychaete annelids.3. The use as claimed in wherein the stabilizing solution is an aqueous solution comprising salts claim 1 , and confers on the composition according to the invention a pH of between 6.5 and 7.6.4. The use as claimed in claim 1 , wherein the stabilizing solution is an aqueous solution comprising 90 mM of NaCl claim 1 , 23 mM of Na gluconate claim 1 , 2.5 mM of CaCl claim 1 , 27 mM of Na acetate claim 1 , 1.5 mM of MgCl claim 1 , 5 mM of KCl claim 1 , and a pH of 7.1±0.5.5. The use as claimed in claim 1 , wherein the organ preservation solution is an aqueous solution having a pH of between 6.5 and 7.5 and comprising salts claim 1 , sugars; antioxidants; active agents; and optionally.6. The use as claimed in claim 1 , wherein the extracellular hemoglobin of annelids claim 1 , globin protomers thereof and/or globins thereof is present at a concentration claim 1 , relative to the final volume of composition claim 1 , of between 0.001 mg/ml and 100 mg/ml claim 1 , and in that the composition has an osmolarity of between 250 and 350 mOsm/l.7. The use of an aqueous solution comprising sodium ...

SOLUTIONS, SYSTEMS AND METHODS FOR CELL, TISSUE AND ORGAN PRESERVATION

This disclosure provides solutions, systems, and methods for cell, tissue, and/or organ preservation. Some preservation solutions may include any combination of a balanced salt solution, electrolytes, antibiotic agents, antimycotic agents, protease inhibitors, anti-oxidants, simple sugars, starches impermeant ions, uric acid and/or amino acids. Some preservation solutions may also include hydrolyzed collagen. The preservation solutions including hydrolyzed collagen may be used alone or as part of a kit to preserve cells, tissue, or organs. The solution may also be used in connection with one or more medical procedures, for example organ transplantation. 1. A preservation solution for storage of organs , tissues or cells comprising:a balanced isotonic solution, andhydrolyzed collagen.2. The preservation solution according to claim 1 , wherein the balanced isotonic solution comprises sodium claim 1 , potassium claim 1 , calcium claim 1 , magnesium and chloride.3. The preservation solution according to claim 1 , wherein the concentration of hydrolyzed collagen in the solution is between about 1 and about 10 mg/ml.4. The preservation solution according to claim 1 , further comprising at least one antibiotic.5. The preservation solution according to claim 1 , further comprising at least one antimycotic.6. The preservation solution according to claim 1 , further comprising at least one protease inhibitor.7. The preservation solution according to claim 1 , further comprising at least one impermeant anion.8. The preservation solution according to claim 1 , further comprising at least one antifreeze protein.9. The preservation solution according to claim 1 , further comprising at least one synthetic ice blocker.10. A method for preserving organs claim 1 , tissue and cells comprising:harvesting an organ, tissue or cells;submerging the organ, tissue or cells in a bath of a solution, the solution comprising an aqueous solution of hydrolyzed collagen.11. The preservation method ...

Desiccated Biologics And Methods Of Preparing The Same

The present invention provides compositions comprising desiccated biologics comprising a cell, protein, virus, nucleic acid, carbohydrate, or lipid, or any combination thereof, along with at least one membrane penetrable sugar, and at least one membrane impenetrable sugar, wherein the moisture content is from 5% to 95%, and to methods of preparing the same, and to methods of treating animals using the same. 1. A method of preserving a red blood cell or platelet comprising:contacting the red blood cell or platelet with at least one membrane penetrable sugar and at least one membrane impenetrable sugar; anddrying the red blood cell or platelet to a final moisture content from about 5% to about 90%.2. The method of wherein the membrane penetrable sugar is trehalose.3. The method of wherein the membrane impenetrable sugar is dextran.4. The method of wherein the moisture content is from about 15% to about 40%.5. The method of wherein the moisture content is from about 20% to about 25%.6. The method of wherein the drying is by vacuum desiccation.7. The method of wherein the drying occurs at a temperature from about 0° C. to about 40° C. for about 1 hours to about 4 hours.8. The method of wherein the drying occurs at a temperature from about 32° C. to about 34° C. for about 3 hours.9. The method of further comprising storing the red blood cell or platelet in a vacuum sealed container in the presence or absence of a desiccant.10. The method of further comprising rehydrating the red blood cell or platelet.11. The method of wherein the rehydrating comprises contacting the red blood cell or platelet with water claim 10 , optionally followed by saline.12. The method of wherein when a platelet is preserved claim 1 , the membrane penetrable sugar is trehalose claim 1 , the membrane impenetrable sugar is dextran claim 1 , and the moisture content is about 15%.13. The method of wherein when a red blood cell is preserved claim 1 , the membrane penetrable sugar is trehalose claim 1 , ...

COMPOSITIONS AND METHODS FOR THE MODULATION OF HEMOGLOBIN (S)

This invention provides pharmaceutical compositions for the aliosteric modulation of hemoglobin (S) and methods for their use in treating disorders mediated by hemoglobin (S) and disorders that would benefit from tissue and/or cellular oxygenation. 1. A composition comprising from about 1 mg to about 10 g of a compound selected from the group consisting of a compound in Table 1 and at least a pharmaceutically acceptable excipient , carrier or diluent.2. The composition of claim 1 , wherein the compound is compound 12 in Table 1.3. A blood composition comprising blood and one or more compounds selected from the group consisting of a compound in Table 1 claim 1 ,wherein said blood is comprised of red blood cells and plasma, andwherein at least 20% of said one or more compounds in the blood is bound to said red blood cells under physiological conditions.4. The blood composition of claim 3 , wherein at least 30% of said one or more compounds is bound to said red blood cells.5. The blood composition of claim 3 , wherein at least 50% of said one or more compounds is bound to said red blood cells.6. The blood composition of claim 3 , wherein at least 80% of said one or more compounds is bound to said red blood cells.7. The blood composition of claim 3 , wherein at least 90% of said one or more compounds is bound to said red blood cells.8. The blood composition of claim 3 , wherein said composition is compound 12 in Table 1.9. The blood composition of claim 3 , wherein at least a part of said red blood cells is sickled claim 3 , and at least a part of said hemoglobin is bound to said compound.10. The blood composition of claim 3 , wherein said blood is free of or substantially free of hemoglobin.11. A blood composition comprising an adduct formed from blood and one more or compounds selected from the group consisting of a compound in Table 1 claim 3 ,wherein said blood is comprised of red blood cells and plasma,wherein said adduct is distributed under steady state ...

TECHNIQUE FOR REGULATING REGENERATION OF TISSUE OR FAULTY OR ABNORMAL PART IN ORGAN USING NELL-1

The object aims to form and maintain a cell, a tissue or an organ induced by differentiation. Disclosed is a composition for inducing the differentiation of a cell capable of being differentiated in a given direction to thereby produce a cell, a tissue or an organ through the further induction of the differentiation in the given direction. The composition comprises NELL-1 or a substance which can be altered so as to act as NELL-1 upon the differentiation. Also disclosed is a composition for maintaining a cell, a tissue or an organ produced by the induction of the differentiation. 1100.-. (canceled)101. A method for inducing differentiation of a cell having been directed to a given differentiation , to a further differentiated cell , tissue or organ directed to the given differentiation , wherein the cell is contacted with an in vivo incubator comprising a container , a scaffold in contact with human NELL-1 , a blood vessel pedicle and a fat tissue pedicle wherein the in vivo incubator is for heterotopically forming the further differentiated cell , tissue or organ directed to the given differentiation in the presence of the fat tissue pedicle and the blood vessel pedicle , wherein the blood vessel pedicle supports the fat tissue pediclewherein the cell having been directed to a given differentiation is a somatic stem cell directed to differentiation of hematopoietic tissue or epithelial tissue.102. The method according to claim 101 , wherein the somatic stem cell present in the hematopoietic tissue is a hematopoietic stem cell claim 101 , which is a mother cell of a blood cell having self repair capability and multipotency.103. The method according to claim 101 , wherein the somatic stem cell present in the epithelial tissue is a stem cell having been directed to differentiation of epithelial tissue claim 101 , which is a mother cell of epithelial system cell having self repair capability and multipotency.104. The method according to claim 101 , wherein the somatic ...

MEDIUM AND METHODS FOR THE STORAGE OF RED BLOOD CELLS

An aqueous storage solution for the storage of red blood cells, comprising an aqueous solution and at least one lipid, wherein the at least one lipid is effective in suppressing hemolysis in red blood cells and wherein the at least one lipid is emulsified within the aqueous solution. 1. An aqueous storage solution for the storage of red blood cells , comprising:an aqueous solution;at least one lipid, wherein the at least one lipid is effective in suppressing hemolysis in red blood cells;wherein the at least one lipid is emulsified within the aqueous solution.2. The aqueous storage solution of claim 1 , wherein the at least one lipid comprises at least one of lecithin claim 1 , vitamin E claim 1 , sphingomyelin claim 1 , phosphatidylethanolamine claim 1 , phosphatidylserine claim 1 , phosphatidylcholine claim 1 , and cholesterol.3. The aqueous storage solution of claim 1 , further comprising red blood cells.4. The aqueous storage solution of claim 3 , wherein the red blood cells comprise a volume of concentrated red blood cells in the range of 180 to 250 mL claim 3 , and the aqueous solution comprises a volume in the range of 80 to 150 mL.5. The aqueous storage solution of claim 1 , further comprising a pH of about 5.0 and being substantially isotonic.6. The aqueous storage solution of claim 1 , further comprising a pH of about 8.0 or higher and being generally hypotonic.7. The aqueous storage solution of claim 3 , further comprising a non-PVC blood container to hold the aqueous storage solution claim 3 , wherein the blood container does not include a plasticizer.8. The aqueous storage solution of claim 7 , wherein the blood container comprises at least one of a polyolefin claim 7 , ethylene vinyl acetate claim 7 , and block copolymer.9. The aqueous storage solution of claim 1 , wherein the aqueous solution comprises at least one of sodium chloride claim 1 , glucose claim 1 , mannitol claim 1 , adenine claim 1 , sodium citrate claim 1 , and sodium phosphate dibasic. ...

METHOD FOR CRYOPRESERVING SHEET-SHAPED CELL CULTURE

Methods are disclosed of freezing, cryopreserving, and transferring a frozen sheet-shaped cell culture. The method of freezing includes (1) a step of immersing in a cryopreservation solution a sheet-shaped cell culture supported by a mesh-shaped support body; (2) a step of removing the cryopreservation solution adhered to the sheet-shaped cell culture, while keeping the sheet-shaped cell culture supported by the mesh-shaped support body; (3) a step of enclosing the sheet-shaped cell culture in a cold-resistant film, an upper surface and a lower surface of the sheet-shaped cell culture being covered by the mesh-shaped support body; and (4) a step of freezing the sheet-shaped cell culture. 1. A method of freezing a sheet-shaped cell culture , comprising:(1) a step of immersing in a cryopreservation solution a sheet-shaped cell culture supported by a mesh-shaped support body;(2) a step of removing the cryopreservation solution adhered to the sheet-shaped cell culture, while keeping the sheet-shaped cell culture supported by the mesh-shaped support body;(3) a step of enclosing the sheet-shaped cell culture in a cold-resistant film, an upper surface and a lower surface of the sheet-shaped cell culture being covered by the mesh-shaped support body; and(4) a step of freezing the sheet-shaped cell culture.2. The method according to claim 1 , wherein in the step (1) claim 1 , the sheet-shaped cell culture is immersed in the cryopreservation solution for 1 to 30 minutes.3. The method according to claim 1 , wherein in the step (2) claim 1 , the cryopreservation solution adhered to the sheet-shaped cell culture is removed by dropping through the mesh-shaped support body.4. The method according to claim 1 , wherein in the step (3) claim 1 , the sheet-shaped cell culture is enclosed in the cold-resistant film in such a manner that a hermetically sealed state can be maintained.5. The method according to claim 1 , wherein in the step (4) claim 1 , the sheet-shaped cell culture is ...

USE OF SEDOHEPTULOSE FOR PREVENTION OR TREATMENT OF INFLAMMATION

The invention discloses sedoheptulose for use in the prevention or treatment of inflammation. 116.-. (canceled)18. The method of claim 17 , wherein the inflammation is a chronic inflammation.19. The method of claim 17 , wherein the inflammation is a systemic inflammatory response syndrome (SIRS) or sepsis.20. The method of claim 19 , wherein the inflammation is further defined as massive systemic inflammation.21. The method of claim 20 , wherein the massive systemic inflammation is in response to polytrauma claim 20 , in response to infection claim 20 , includes organ-specific manifestations claim 20 , acute respiratory distress syndrome (ARDS) and/or multiple organ dysfunction syndrome (MODS).22. The method of claim 17 , wherein the inflammation is meta-inflammation or inflammation defined as chronic (low grade) systemic inflammation as reflected by increased levels of pro-inflammatory cytokines or other inflammation markers in peripheral blood and involved in aging claim 17 , adiposity claim 17 , atherosclerosis claim 17 , impaired glucose tolerance and type 2 diabetes claim 17 , neurodegenerative disorders claim 17 , major depressive disorder (MDD) claim 17 , or cancer.23. The method of claim 22 , wherein chronic (low grade) systemic inflammation is reflected by increased levels of tumor necrosis factor alpha claim 22 , interleukin-6 claim 22 , c-reactive protein claim 22 , or serum amyloid alpha.24. The method of claim 17 , wherein the inflammation is involved claim 17 , causally or otherwise claim 17 , in the pathogenesis of an inflammation-related disorder claim 17 , impaired glucose tolerance claim 17 , diabetes mellitus and diabetic complications claim 17 , metabolic syndrome claim 17 , atherosclerosis claim 17 , inflammatory bowel disease claim 17 , colitis ulcerosa and rarer entities claim 17 , chronic inflammatory liver disease including chronic viral hepatitis claim 17 , autoimmune hepatitis claim 17 , primary sclerosing cholangitis and fatty liver ...

System for Extended Storage of Red Blood Cells and Methods of Use

A system and methodology for the preservation of red blood cells is described in which red blood cells are oxygen or oxygen and carbon dioxide depleted, treated and are stored in an anaerobic environment to optimize preparation for transfusion. More particularly, a system and method for extended storage of red blood cells from collection to transfusion that optimizes red blood cells prior to transfusion is described. 139.-. (canceled)40. A method for preparing whole blood for transfusion comprising:obtaining whole blood;depleting oxygen and carbon dioxide from said whole blood to prepare oxygen and carbon dioxide depleted whole blood;storing said oxygen and carbon dioxide depleted whole blood in a anaerobic storage bag comprising an outer bag having a barrier film that is impermeable to oxygen and carbon dioxide, an inner bag in contact with said red blood cells, and an oxygen and carbon dioxide sorbent disposed between said inner bag and said outer bag.41. The method of claim 40 , further comprising oxygenating said stored oxygen and carbon dioxide depleted whole blood.42. The method of claim 40 , further comprising leukoreducing said whole blood prior to said depleting.43. The method of claim 40 , wherein said inner bag comprises polyvinyl chloride (PVC).44. The method of claim 43 , wherein said inner bag comprises di(2-ethylhexyl) phthalate (DEHP)-plasticized PVC.45. The method of claim 40 , further comprising inactivating pathogens before storage of said oxygen and carbon dioxide depleted whole blood.46. The method of claim 45 , wherein said inactivating pathogens comprises riboflavin and light therapy.47. The method of claim 40 , wherein said depleting oxygen and carbon dioxide comprises passing said whole blood through a combined leukoreduction and oxygen and carbon dioxide depletion device.48. The method of claim 47 , wherein said depleting oxygen and carbon dioxide from said whole blood comprises passing said whole blood through a device having a disposable ...

PLATELET STORAGE METHODS AND COMPOSITIONS FOR SAME

Disclosed are compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier. 1. A composition for platelet storage or treatment comprising a compound selected from a RAC inhibitor , a CDC42 inhibitor , a RHOA inhibitor , or a combination thereof , and a pharmaceutically acceptable carrier.232.-. (canceled) This application claims priority to and benefit of U.S. Provisional Application Ser. No. 62/013,662, filed Jun. 18, 2014, of sane title, in its entirety for all purposes.Patients with low platelet counts often require platelet transfusion. This is particularly crucial in the treatment of patients with cancer or massive trauma. The use of platelet transfusions has increased dramatically since 1980s, but a safe, long-term platelet storage method remains unavailable. The demonstration of successful, refrigerated storage of platelets for extended lengths of time, for example, 7 days or longer, would dramatically change the current practice of platelet transfusion in the Western World. Approximately 3,000,000 doses of platelets are used in the United States every year, and account for sales of ˜$1.5 Billion annually. The current short shelf-life represents a major handicap to convert platelet products into effective commodities. Depending on the time of the year, month or even week, up to 20% of products can be wasted due to expiration. In the meantime, there are moments of platelets shortages due to unpredictable increased usage. The extension of platelet product shelf-life would strengthen the national inventory of platelets for oncological and trauma patients. An estimated 10-fold increase in the need of platelet and plasma products is expected by the US government in ...

LONG TERM STORAGE AND PRESERVATION OF PLATELETS

Provided herein, inter alia, are compositions and methods for preserving platelets in a lesion-free and functional state during extended storage periods of up to 15 days as well as methods and kits for utilizing the same. In contrast to currently available compositions and techniques for preserving platelets, platelets stored in the compositions disclosed herein are characterized by a marked decrease in “storage-lesions,” which are associated with attenuated hemostatic function. During platelet storage, the compositions disclosed herein (1) maintain and/or restore platelet energy states and morphology; (2) maintain active metabolism and buffering; (3) preserve and/or promote nitric oxide production; and (4) prevent microparticle formation, aggregation and activation during storage. As such, long term preservation in the compositions described herein produce platelets that are fully functional and lesion-free. 1. A composition for preserving platelets comprising: a physiological salt solution , glutathione , ascorbic acid , adenosine , dichloroacetate , and less than 1 μM calcium ions.2. A composition for preserving platelets comprising: a physiological salt solution , glutathione , ascorbic acid , adenosine , and less than 1 μM calcium ions.3. The composition of or , wherein the physiological salt solution comprises one or more salts selected from the group consisting of potassium chloride , potassium phosphate , magnesium chloride , magnesium sulfate , sodium chloride , sodium bicarbonate and sodium phosphate.4. The composition of any one of - , comprising about 4-5 mM of potassium chloride.5. The composition of any one of - , comprising about 100-115 mM sodium chloride.6. The composition of any one of - , comprising about 10-40 mM sodium phosphate.7. The composition of any one of - , further comprising about 2.5-5 mM creatine.8. The composition of any one of or - , comprising about 0.001-0.5 mM dichloroacetate.9. The composition of any one of - , further ...

METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT

The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules for their use in improving organ viability and/or longevity. 1. A method for increasing the viability , functionality or longevity of an organ or portion thereof comprising contacting a donor organism having said organ or portion thereof with composition comprising a modified mRNA , said modified mRNA comprising a nucleic acid sequence having greater than 80% identity to SEQ ID NO: 257 , wherein said organ is a heart and wherein said modified mRNA composition is formulated in saline.2. The method of claim 1 , wherein said contacting the donor organism occurs either prior to any procedure to remove the heart or during heart removal.3. The method of claim 2 , wherein the donor organism is a mammal.4. The method of claim 3 , wherein the mammal is human.5. The method of claim 2 , wherein said contacting is prior to heart removal and is effected by delivery to the blood of the donor.6. The method of wherein delivery to the blood is facilitated at least in part by the use of claim 5 , or in combination with claim 5 , a medical device claim 5 , system or component.7. The method of claim 2 , wherein said contacting is during heart-removal and is effected by delivery to the blood of the donor.8. The method of wherein delivery to the blood is facilitated at least in part by the use of claim 7 , or in combination with claim 7 , a medical device claim 7 , system or component.9. The method of claim 8 , wherein the medical device is an ex-vivo organ care system.10. The method of claim 1 , wherein the formulated modified mRNA encodes VEGF.11. A method of reducing reperfusion injury to an organ comprising contacting said organ with a formulated modified mRNA claim 1 , said modified mRNA comprising a nucleic acid sequence having greater than 80% identity to SEQ ID NO: 257.12. A method of reducing transplant rejection in an organism comprising contacting said organism ...

Reperfusion with Omega-3 Glycerides Promotes Donor Organ Protection for Transplantation

It has been discovered that isolated organs and tissues perfused/reperfused in perfusion buffer to which omega-3 glyceride oil had been added retain higher levels of function than if perfused/reperfused without the omega-3 glycerides. Isolated hearts reperfused ex vivo after induced ischemia in n-3 triglyceride perfusion emulsion maintained a normal heart rate and normal LVDP and showed a dramatically reduced frequency of arrhythmias compared to control hearts. Further, test hearts reperfused with n-3 oil triglyceride emulsion showed a decrease in creatine kinase and upregulation of certain beneficial proteins including the anti-apoptotic gene marker Bcl-2. 1. An omega-3 oil in water emulsion for perfusion of an organ or tissue ex vivo , wherein the emulsion comprises(a) a perfusion buffer suitable for organ or tissue preservation and transplantation, (i) comprises from about 10% to about 99% omega-3 diglyceride, omega-3 triglyceride or combinations thereof by weight per total weight of the omega-3 oil, and at least about 20% to about 99% of the total acyl groups of the diglycerides and triglycerides comprise EPA or DHA, and', '(ii) comprises less than 10% omega-6 fatty acids by weight per total weight of the omega-3 oil,, '(b) less than 7% of an omega-3 oil by weight in grams per 100 ml of perfusion buffer, wherein the omega-3 oil'}(c) less than 10% omega-6 oil by weight in grams per 100 ml of perfusion buffer, and(d) the mean diameter of lipid droplets in the emulsion is from about 100 nm to less than about 5 microns.2. The omega-3 oil in water emulsion of claim 1 , wherein the emulsion comprises from about 0.5% to about 1% omega-3 oil by weight in grams per 100 ml of perfusion buffer.3. The omega-3 oil in water emulsion of claim 1 , wherein the emulsion comprises from about 1% to about 5% omega-3 oil by weight in grams per 100 ml of perfusion buffer.4. The omega-3 oil in water emulsion of claim 1 , wherein the emulsion comprises from about 5% to less than 7% ...

ORGAN PERFUSION SYSTEMS

An organ perfusion system comprises: a perfusion fluid circuit () arranged to circulate perfusion fluid through the organ; a surrogate organ () arranged to be connected into the circuit in place of the organ so that the circuit can circulate fluid through the surrogate organ; and organ sensing means arranged to distinguish between the presence of the organ in the circuit and the presence of the surrogate organ in the circuit. The sensing means may comprise one or more pressure sensors (), or a flow meter (). Further aspects relate to adjusting the content of at least one component, such as oxygen or a nutrient, in the perfusion fluid. Bubble detection means (), and means () to measure the amount of fluid secreted by or leaked from the organ, may also be provided. 1. A method of operating a perfusion system to perfuse a bodily organ , the method comprising:providing a perfusion system, the system comprising a perfusion fluid circuit arranged to circulate perfusion fluid through the bodily organ, a surrogate organ arranged to be connected into the circuit in place of the bodily organ so that the circuit can circulate fluid through the surrogate organ, and an organ sensing system arranged to distinguish between a presence of the bodily organ in the circuit and a presence of the surrogate organ in the circuit;sensing, using the sensing system, the presence of the surrogate organ in the circuit;circulating perfusion fluid through the circuit and the surrogate organ while adjusting at least one parameter of the perfusion fluid to bring it within a target range;disconnecting the surrogate organ from the circuit and connecting the bodily organ into the circuit;sensing, using the sensing system, the presence of the bodily organ in the circuit; andcirculating the perfusion fluid through the circuit and the bodily organ.2. The method of wherein the bodily organ provides a first resistance to flow of the perfusion fluid through the circuit claim 1 , the surrogate organ provides ...

VITRIFICATION-CRYOPRESERVATION IMPLEMENT FOR CELLS OR TISSUES

The present invention relates to a jig for vitrification cryopreservation of cell or tissue, having a metallic support, and a vitrification solution absorber including an adhesion layer and a vitrification solution-absorbing layer on the metallic support in the order from the side closer to the metallic support. 1. A jig for vitrification cryopreservation of cell or tissue , comprising:a metallic support, anda vitrification solution absorber including an adhesion layer and a vitrification solution-absorbing layer on the metallic support in the order from the side closer to the metallic support.2. The jig for vitrification cryopreservation of cell or tissue according to claim 1 , wherein the vitrification solution-absorbing layer is a paper or a nonwoven fabric.3. The jig for vitrification cryopreservation of cell or tissue according to claim 2 , wherein the basis weight of the vitrification solution-absorbing layer is 20 g/mor more.4. The jig for vitrification cryopreservation of cell or tissue according to claim 2 , wherein the density of the vitrification solution-absorbing layer is 0.25 g/cmor less.5. The jig for vitrification cryopreservation of cell or tissue according to claim 2 , wherein the density of the vitrification solution-absorbing layer is 0.5 g/cmor less and the basis weight is 100 g/mor less.6. The jig for vitrification cryopreservation of cell or tissue according to claim 2 , wherein the vitrification solution-absorbing layer has a fiber of 4 μm or less in average fiber diameter.7. The jig for vitrification cryopreservation of cell or tissue according to claim 1 , wherein the adhesion layer contains at least one of polyvinyl pyrrolidone and polyvinyl alcohol of which the degree of polymerization is 700 to 3000.8. A method of vitrification-cryopreserving a cell or tissue claim 1 , comprising the steps of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'providing a jig for vitrification cryopreservation of cell or tissue according to ;'}dropping a ...

Preservation of Cellular Components from Cells with a Preservative

This invention relates to a preservative solution and a method to preserve whole blood for cellular and molecular analysis. 1. A reagent for preserving cells from a biological sample for subsequent isolation of cellular components comprising an effective amount of glyoxal.2. The reagent of comprising about 0.1% to about 0.5% glyoxal.3. The reagent of comprising about 0.2% glyoxal.4. The reagent of further comprising additional agents selected from the group consisting of phosphates claim 1 , salts claim 1 , bases and anti-coagulants.5. The reagent of further comprising sodium phosphate dibasic heptahydrate claim 1 , potassium phosphate monobasic claim 1 , sodium chloride claim 1 , disodium salt dihydrate claim 1 , sodium hydroxide claim 1 , crosslinked poly ethylene glycol of molecular weight 20K claim 1 , and ethylenediamine tetraacetic acid disodium salt dehydrate.6. A method for preserving cellular components comprising obtaining a biological sample and adding a reagent comprising an effective amount of glyoxal claim 1 , wherein said method preserves the cellular components for a sufficient period of time.7. The method of wherein the biological sample is selected from the group consisting of whole blood and bone marrow.8. The method of wherein the biological sample is whole blood.9. The method of wherein the cellular components are nucleic acids10. The method of wherein the cellular component is coding RNA11. The method of wherein the reagent comprises about 0.1% to about 0.5% glyoxal.12. The method of wherein the reagent comprises about 0.2% glyoxal.13. The method of wherein the reagent further comprises additional agents selected from the group consisting of phosphates claim 6 , salts claim 6 , bases and anti-coagulants.14. The method of wherein the reagent further comprises sodium phosphate dibasic heptahydrate claim 6 , potassium phosphate monobasic claim 6 , sodium chloride claim 6 , disodium salt dihydrate claim 6 , sodium hydroxide claim 6 , crosslinked ...

PERFUSION MANIFOLD ASSEMBLY

A perfusion manifold assembly is described that allows for perfusion of a microfluidic device, such as an organ on a chip microfluidic device comprising cells that mimic cells in an organ in the body, that is detachably linked with said assembly so that fluid enters ports of the microfluidic device from a fluid reservoir, optionally without tubing, at a controllable flow rate. 1. A perfusion manifold assembly , comprising i) one or more fluid reservoirs , ii) a fluidic backplane positioned under , and in fluidic communication with , said fluid reservoirs , said fluidic backplane comprising fluid channels that terminate at ports.2. The assembly of claim 1 , wherein said fluidic backplane comprises a fluid resistor.3. The assembly of claim 1 , further comprising iii) a skirt claim 1 , said skirt comprising a guide mechanism.4. The assembly of claim 3 , wherein said guide mechanism comprises one or more side tracks.5. The assembly of claim 4 , wherein said one or more side tracks are configured for engaging a microfluidic device positioned in a microfluidic device carrier having one or more outer edges configured to slideably engage said one or more side tracks.6. The assembly of claim 2 , wherein said resistor comprises serpentine channels.7. The assembly of claim 6 , wherein said fluidic backplane comprises linear fluid channels in fluidic communication with said serpentine channels claim 6 , said linear channels terminating at one or more ports.8. The assembly of claim 1 , further comprising a cover for said fluid reservoirs claim 1 , wherein said cover comprises a plurality of ports.9. The assembly of claim 8 , wherein said ports are through-hole ports.10. The assembly of claim 8 , wherein said ports are associated with filters.11. The assembly of claim 10 , wherein said filters are positioned above corresponding holes in a gasket.12. The assembly of claim 4 , wherein said side track comprises a closed first end proximal to said reservoirs and an opened second end ...

TISSUE PRESERVATION SYSTEM

The present invention provides a method and apparatus for tissue, such as an allograft, storage and preservation for extended periods of time at room temperature in a sterile tissue culture chamber. The invention further provides a process for maintaining the sterility of tissue using the apparatus as described. 1. A process for ligament tissue preservation comprising storing the ligament tissue at room temperature in a container comprising culture media for from about 7 to about 70 days prior to implantation.2. The process of claim 1 , comprising testing the tissue for viability at least once prior to implantation in a patient.3. The process of claim 2 , wherein testing for viability comprises assaying media withdrawn from said container.4. The process of claim 2 , wherein testing for viability comprises adding a resazurin solution to the media and determining a fluorescence level claim 2 , wherein increased fluorescence indicates higher cell viability.5. The process of claim 1 , comprising storing the tissue for from 29 to about 70 days.6. The process of comprising changing said media at least once during the storing.7. The process of claim 6 , comprising changing the media about once every two weeks during the storing.8. The process of claim 1 , wherein at least about 70% of cells of said ligament tissue preserved by said process remain viable after 45 days of storing.9. The process of claim 1 , wherein the media is serum free media.10. The process of claim 9 , wherein the media comprises Dulbecco's Modified Eagle Medium (DMEM) claim 9 , high or low concentrations of glucose claim 9 , antibiotic compounds claim 9 , antimycotic compounds claim 9 , dexamethasone claim 9 , ascorbate 2-phosphate claim 9 , L-proline claim 9 , sodium pyruvate claim 9 , Transforming growth factor-β3(TGF-β3) claim 9 , insulin claim 9 , transferrin claim 9 , and selenous acid.11. The process of claim 1 , wherein the ligament tissue comprises an allograft claim 1 , the process comprising ...

Composition for Organ, Tissue, or Cell Transplantation, Kit, and Transplantation Method

Disclosed are: a composition for organ, tissue or cell transplantation, containing, as an active ingredient, a peptide comprising the amino acid sequence of SEQ ID NO: 1, a peptide having at least 80% sequence homology with the amino acid sequence, or a peptide which is a fragment thereof; a kit comprising the composition; or a method using the composition. By using the composition, the kit, or the method, the viability and/or function of an organ, tissue, or cell after transplantation are strengthened and an organ, tissue or cell isolated from a living body is preserved temporarily without damage. 1. A composition for organ , tissue or cell transplantation , comprising:a peptide comprising the amino acid sequence of SEQ ID NO: 1, a peptide having at least 80% sequence homology with the amino acid sequence or a fragment thereof as an active ingredient.2. The composition of claim 1 , wherein the fragment is composed of three or more amino acids.3. The composition of claim 1 , wherein the composition is administered into a donor and/or recipient.4. The composition of claim 3 , wherein the composition is administered in any one or more stages before claim 3 , during and after transplantation.5. The composition of claim 1 , wherein the composition is to store an organ claim 1 , tissue or cells isolated from a donor.6. The composition of claim 1 , wherein the composition comprises a sufficient amount of the peptide as the active ingredient to strengthen the survivability or function of the organ claim 1 , tissue or cell after transplanted into a recipient.7. The composition of claim 6 , wherein the composition comprises the peptide as the active ingredient at a concentration of 10 to 1000 mg/L with respect to the total volume of the composition.8. The composition of claim 7 , wherein the composition comprises the peptide as the active ingredient at a concentration of 50 to 500 mg/L with respect to the total volume of the composition.9. A kit for organ claim 7 , tissue or ...

METHODS TO IMPROVE ORGAN VIABILITY

The present disclosure provides methods to improve the viability of an organ, or organs, by continuously administering a composition comprising NOgas directly to the organ(s). 1. A method to improve the viability of an organ intended for transplant , the method comprising continuously administering a composition comprising 20 ppm or less of NOgas directly to the organ via an organ perfusion system or ventilation.2. The method of claim 1 , where in the composition is administered for at least one hour but not more than 12 hours.3. The method of claim 1 , wherein the composition is administered after the organ has been harvested from a donor.4. The method of claim 1 , wherein the composition is administered while the organ is within a brain dead donor.5. The method of claim 1 , wherein the organ is selected from the group consisting of lungs claim 1 , heart claim 1 , liver claim 1 , kidney claim 1 , pancreas claim 1 , intestine claim 1 , thymus claim 1 , and cornea.6. The method of claim 1 , wherein the amount of NOis about 10 ppm to about 15 ppm.7. The method of claim 1 , wherein the amount of NOis about 5 ppm to about 10 ppm.8. The method of claim 1 , wherein the amount of NOis about 1 ppm to about 5 ppm.9. The method of claim 1 , wherein the composition is an organ perfusion solution and optionally further comprises one or more additional compound(s).10. The method of claim 9 , wherein the perfusion solution is an acellular perfusion solution.11. The method of claim 1 , wherein the method further comprises administering to the organ a composition comprising about 20 ppm to about 40 ppm of NOgas (“a loading dose”) for up to about 1 hour (“a loading period”) immediately before continuously administering the composition comprising 20 ppm or less of NOgas.12. The method of claim 11 , wherein the loading dose composition is a perfusion solution.13. The method of claim 12 , wherein the perfusion solution is an acellular perfusion solution.14. The method of claim 11 , ...

METHODS AND COMPOSITIONS FOR THE PRESERVATION OF TISSUE

Described herein are methods of preserving a tissue of a subject, such as a brain or a portion thereof. The methods include washing the tissue by perfusing the tissue with a wash fluid comprising an aqueous solution; fixing the tissue by perfusing the tissue with a fixation fluid comprising an aldehyde; and cryoprotecting the tissue by perfusing the tissue with a cryoprotection fluid comprising a vitrification agent. The wash fluid, the fixation fluid, and/or the cryoprotection fluid can include a dye or a contrast agent to monitor perfusion of the fluid through the tissue. In certain embodiments, the cryoprotection fluid has a vitrification temperature of about −80° C. or higher. The wash fluid can further include one or more of an ion channel blocker, a calcium chelator, a thrombolytic agent, an anti-platelet, a respiratory poison, or a synaptic poison. Also described herein are methods of analyzing the preserved tissue. 2. A method of preserving a tissue of a subject , comprisingwashing the tissue by perfusing the tissue with a wash fluid comprising an aqueous solution;fixing the tissue by perfusing the tissue with a fixation fluid comprising an aldehyde; andcryoprotecting the tissue by perfusing the tissue with a cryoprotection fluid comprising a vitrification agent;the wash fluid, the fixing fluid, or the cryoprotection fluid comprising a dye or a contrast agent.3. A method of preserving a tissue of a subject , comprisingwashing the tissue by perfusing the tissue with a wash fluid comprising an aqueous solution;fixing the tissue by perfusing the tissue with a fixation fluid comprising an aldehyde; andcryoprotecting the tissue by perfusing the tissue with a cryoprotection fluid comprising a vitrification agent, the cryoprotection fluid having a vitrification temperature of about −80° C. or higher.4. A method of preserving a tissue of a subject , comprisingwashing the tissue by perfusing the tissue with a wash fluid comprising (1) an aqueous solution, and (2) any ...

CYCLOSPORIN ANALOG AND USE THEREOF

The present invention provides a cyclosporin analog and use thereof, and in particular relates to a compound and use thereof as a mitochondrial protective agent for storing a donated organ. The compound is a compound of formula 1 or a salt thereof, wherein n is 2-5, and Rand Rare independently selected from H or C-Calkyl, wherein Rand Rcan be linked together to form a C-Cheteroalkyl ring. 1. (canceled)2. (canceled)5. The method of wherein the organ is a kidney.7. The method of wherein the donor is a live donor.8. (canceled)9. A The method of claim 3 , wherein the dose of the compound is 0.1 to 10 mg/kg.10. The method of claim 9 , wherein the dose of the compound is 1 to 3 mg/kg.11. The method of claim 3 , wherein the compound is administered to a live organ donor prior to an organ transplantation.12. The method of claim 3 , wherein the compound is administered together with one or more further active substances.13. The method of claim 3 , further comprising administering the compound to the organ after removing the organ from the organ donor and prior to a transplantation.14. The method of claim 3 , further comprising administering the compound to an organ recipient after organ transplantation; or shortly before receiving the organ.15. The method of claim 3 , wherein the compound is administered systemically.16. The method of claim 3 , wherein the compound is administered shortly before organ removal surgery claim 3 , up to 1 to 8 hours before surgery claim 3 , or during organ removal surgery.17. The method of claim 3 , wherein the compound is administered to protect the organ against ischaemia-reperfusion injury.18. The method of claim 3 , wherein the compound is administered to protect the organ in a period of time between removing the organ from the donor's blood supply to reconnection to a donor recipient's blood supply.19. The method of claim 3 , wherein the compound is formulated for intravenous administration to the donor prior to removal of the organ claim 3 ...

PRESERVATION OF STEM CELLS

The invention relates to a field of stem cell preservation and in particular to use of an aqueous solution comprising polyethylene glycol (PEG) having a molecular weight about 35000 Da as an extracellular agent for preserving stem cells. 1. A method of preserving stem cells , comprising: applying to the stem cells an extracellular agent comprising an aqueous solution comprising polyethylene glycol (PEG) having molecular weight ofabout 35000 Da,wherein the solution comprises:about 20 to about 40 mmol/l of raffinose,about 70 to about 140 mmol/l of lactobionic acid,about 1 to about 10 mmol/l of MgSO4,about 10 to about 40 mmol/l of KH2PO4,about 1 to about 6 mmol/l of glutathione,about 1 to about 10 mmol/l of adenosine,about 1 to about 5 mmol/l of allopursine,about 30 to about 150 mmol/l of NaOH,and additionallypH of the solution is in the range of about 6.5 to about 8, andosmolality of the solution is in the range of about 290 to about 320 mOsm/kg.2. The method according to claim 1 , wherein PEG is present in the solution at a concentration of about 0.01 to about 5 mmol/l.3. The method according to claim 1 , wherein PEG is present in the solution at a concentration lower than about 1 mmol/l.4. The method according to claim 1 , wherein PEG is present in the solution at a concentration of about 0.03 mmol/l.5. The method according to claim 1 , wherein the solution comprises Na+ ions at a concentration of at least about 30 mmol/l and K+ ions at a concentration of at least about 10 mmol/l.6. The method according to claim 1 , wherein the solution comprises Na+ ions at a concentration of about 125 mmol/l and K+ ions at a concentration of about 25 mmol/l.7. The method according to claim 1 , wherein the solution comprises30 mmol/l of raffinose ·5H2O,100 mmol/l of lactobionic acid,5 mmol/l of MgSO4. 7H2O,25 mmol/l of KH2PO4,3 mmol/l of glutathione,5 mmol/l of adenosine,1 mmol/l of allopurinol,0.03 mmol/l of polyethylene glycol having molecular weight of about 35000 DaandNaOH in ...

PERFUSION SYSTEMS AND METHODS OF PERFUSING AT LEAST A PORTION OF A SMALL INTESTINE

One embodiment of the invention provides a perfusion system including: a first circuit adapted and configured to circulate a first perfusate through a lumen of a small intestine and a second circuit adapted and configured to circulate a second perfusate through one or more blood vessels of the small intestine. Another aspect of the invention provides a method of perfusing at least a portion of a small intestine. The method includes: circulating a first perfusate through a lumen of the small intestine and circulating a second perfusate through a blood vessel of the small intestine. 1. A perfusion system comprising:a first circuit adapted and configured to circulate a first perfusate through a lumen of a small intestine; anda second circuit adapted and configured to circulate a second perfusate through one or more blood vessels of the small intestine.2. The perfusion system of claim 1 , wherein the first circuit comprises:a first perfusate reservoir;a first length of tubing coupled to the first perfusate reservoir;a second length of tubing coupled to the first perfusate reservoir; anda first pump adapted and configured to circulate the first perfusate from the first perfusate reservoir to the first length of tubing and through the lumen of the small intestine to the second length of tubing.3. The perfusion system of claim 2 , further comprising:a first fitting coupled to the first length of tubing and adapted and configured to form a substantially fluid-tight coupling with a first end of the lumen of the small intestine; anda second fitting coupled to the second length of tubing and adapted and configured to form a substantially fluid-tight coupling with a second end of the lumen of the small intestine.4. The perfusion system of claim 3 , wherein the first fitting and the second fitting are Christmas tree fittings.5. The perfusion system of claim 2 , wherein the first pump is a peristaltic pump.6. The perfusion system of claim 1 , wherein the second circuit comprises: ...

SMALL RUMINANT SEMEN FREEZING DILUENT

The present invention relates to a small ruminant semen freezing diluent, comprising, for each 100 ml, the following components: 2.71 g of trihydroxymethyl aminomethane, 1.4 g of citric acid, 1.0 g of monosaccharide, 5-20 ml of fresh egg yolk, 0-10 ml of osmotic protective agent, 0.1 million IU of penicillin, 0.1 million IU of streptomycin, 50-600 mMol of inositol compounds, 0.1-50 μMol of resveratrol, and the rest of ultra-pure water. In this invention, resveratrol is firstly and successfully applied to the small ruminant semen freezing field, improving the quality of the frozen semen, thereby being low in costs, stable in chemical property, and simple and easy to use. 1. A small ruminant semen freezing diluent , wherein each 100 ml of it includes following components:2.71 g of trishydroxymethyl aminomethane,1.4 g of citric acid,1.0 g of monosaccharide,5-20 ml of fresh egg yolk,0-10 ml of osmotic protective agent,0.1 million IU of penicillin,0.1 million IU of streptomycin,50-600 mMol of inositol compounds,0.1-50 μMol of resveratrol, andthe rest of which ultra-pure water, and whereinthe inositol compounds are one of 1,3-cyclohexanediol, 1,4-cyclohexanediol and 1,3,5-cyclohexanetriol.2. (canceled)3. The small ruminant semen freezing diluent according to claim 1 , wherein the monosaccharide is glucose or fructose.4. The small ruminant semen freezing diluent according to claim 1 , wherein the osmotic protective agent is glycerin or ethylene glycol.5. The small ruminant semen freezing diluent according to claim 1 , wherein the fresh egg yolk has been inactivated at 56° C. for 30 minutes. The present invention relates to the field of animal reproductive physiology and reproductive technology and in particular, to small ruminant semen freezing diluent.Though the research on freezing preservation of livestock semen has been carried out for over 50 years, thawed semen has the vitality only about 30%-50%, and both non-return rate and calving rate after artificial ...

COMPOSITIONS AND METHODS FOR ORGAN PRESERVATION

Disclosed herein are solutions for use with machine perfusion of one or more organs. In some embodiments, the solutions comprise acellular cross-linked hemoglobin in a physiologically acceptable medium. Also disclosed herein are methods for machine perfusion of one or more organs, for example utilizing the disclosed perfusion solutions. In some embodiments, the methods include perfusing an organ with an oxygenated solution (such as the disclosed solutions) which is at a temperature between about 12-37° C., for example at a temperature of about 21° C. 12-. (canceled)3. An organ perfusion solution comprising 3-4 g/dL acellular cross-linked hemoglobin and 10-40 g/L hydroxyethyl starch in a physiologically acceptable medium , wherein the solution has a pH of about 7.55-7.85 at room temperature , an osmolality of about 290-300 mOsm/kg , and a colloid osmotic pressure of about 35-65 mm Hg.4. The solution of claim 3 , wherein the solution has a pH of about 7.6-7.7 claim 3 , an osmolality of about 295-297 claim 3 , and a colloid osmotic pressure of about 58-60.5. The solution of claim 3 , wherein the cross-linked hemoglobin comprises cross-linked bovine hemoglobin having an average molecular weight of about 200-270 kD.6. The solution of claim 5 , wherein the cross-linked bovine hemoglobin comprises cross-linked hemoglobin having an average molecular weight of about 250 kD.7. The solution of claim 6 , wherein the cross-linked bovine hemoglobin is glutaraldehyde cross-linked hemoglobin.89-. (canceled)10. The solution of claim 3 , wherein the physiologically acceptable medium comprises about 100-140 mM sodium ions claim 3 , about 8-18 mM potassium ions claim 3 , about 30-90 mM chloride ions claim 3 , and about 0.2-0.7 mM calcium ions.11. The solution of claim 10 , wherein the physiologically acceptable medium comprises about 100-110 mM sodium ions claim 10 , about 15-18 mM potassium ions claim 10 , about 30-40 mM chloride ions claim 10 , and about 0.2-0.3 mM calcium ions.1213 ...

IMPROVED METHODS FOR CRYOPRESERVATION OF BIOLOGICAL MATERIALS

Broadly speaking, embodiments of the present technique provide apparatus for controlling ice formation, such as during the processes of cryopreservation and freeze drying. In particular, the apparatus provides a mechanism to deliver an ice nucleating material into a biological sample that is to be preserved, without allowing the ice nucleating agent to contact or contaminate the biological matter within the sample. 1. An apparatus for performing ice nucleation , the apparatus comprising:at least one housing, the housing comprising a cavity and at least one permeable housing wall; andan ice nucleating material encapsulated within the cavity.2. The apparatus as claimed in wherein the housing comprises a first permeable housing wall and a second permeable housing wall.3. The apparatus as claimed in wherein the first permeable housing wall is formed of a first layer claim 2 , and the second permeable housing wall is formed of a second layer claim 2 , and wherein the cavity is provided between the first layer and the second layer.4. (canceled)5. The apparatus as claimed in wherein the housing is formed of a permeable material layer having a first portion and a second portion claim 2 , wherein the first permeable housing wall is formed of the first portion of the permeable material layer claim 2 , and the second permeable housing wall is formed of the second portion of the permeable material layer claim 2 , and wherein the cavity is provided between the first portion and the second portion of the permeable material layer.6. (canceled)7. The apparatus as claimed in wherein the housing comprises a housing body and a permeable housing wall claim 1 , wherein the cavity is provided between the housing body and the permeable housing wall.8. (canceled)9. The apparatus as claimed in wherein the housing comprises a housing body claim 1 , a first permeable housing wall and a second permeable housing wall claim 1 ,wherein the housing body is a disc comprising a through hole, the ...

System for Extended Storage of Red Blood Cells and Methods of Use

A system and methodology for the preservation of red blood cells is described in which red blood cells are oxygen or oxygen and carbon dioxide depleted, treated and are stored in an anaerobic environment to optimize preparation for transfusion. More particularly, a system and method for extended storage of red blood cells from collection to transfusion that optimizes red blood cells prior to transfusion is described. 139.-. (canceled)40. A method of preparing red blood cells for transfusion in the treatment of an inherited hemoglobinopathy in a subject in need thereof comprising:obtaining whole blood;separating red blood cells from said whole blood to form packed red blood cells;depleting oxygen and carbon dioxide from said packed red blood cells prior to storage to prepare depleted packed red blood cells; andstoring said depleted packed red blood cells in an anaerobic storage bag comprising an outer bag having a barrier film that is impermeable to oxygen and carbon dioxide, and an inner bag in contact with said red blood cells, wherein said depleted packed red blood cells are maintained in an anaerobic condition, to form stored depleted red blood cells.41. The method of claim 40 , further comprising oxygenating said stored depleted red blood cells.42. The method of claim 40 , further comprising transfusing said red blood cells into a subject in need thereof.43. The method of claim 40 , wherein said inherited hemoglobinopathy is thalassemia.44. The method of claim 40 , wherein said inherited hemoglobinopathy is alpha-thalassemia.45. The method of claim 40 , wherein said inherited hemoglobinopathy is beta-thalassemia.46. The method of claim 40 , wherein said stored depleted red blood cells comprise an initial oxygen saturation of less than 3 Torr.47. The method of claim 40 , wherein said subject in need thereof requires 30 or more units of blood per year.48. The method of claim 40 , wherein said stored depleted red blood cells have higher 24-hr recovery and reduced ...

SOLUTION FOR PRESERVING AND/OR RINSING AN ORGAN TO BE TRANSPLANTED

Disclosed herein is a method comprising: exposing an organ to be transplanted to an aqueous solution comprising: sodium (Na) ions at a concentration between 30 and 150 mmol·L; potassium ions (K) at a concentration between 10 and 40 mmol·L; polyethylene glycol with a molecular weight of 35,000 g·mol(PEG 35000) at a concentration between 2 and 5 g·L, wherein the step of exposing further comprises preserving and/or rinsing and/or reconditioning the organ in the aqueous solution. 1. A method comprising:exposing an organ to be transplanted to an aqueous solution comprising:{'sup': +', '−1, 'sodium (Na) ions at a concentration between 30 and 150 mmol·L;'}{'sup': +', '−1, 'potassium ions (K) at a concentration between 10 and 40 mmol·L;'}{'sup': −1', '−1, 'polyethylene glycol with a molecular weight of 35,000 g·mol(PEG 35000) at a concentration between 2 and 5 g·L,'}wherein the step of exposing further comprises preserving and/or rinsing and/or reconditioning the organ in the aqueous solution.2. The method of claim 1 , wherein the step of preserving is static.3. The method of claim 2 , wherein the temperature of the aqueous solution is between +1 and +12° C.4. The method of claim 1 , wherein the step of preserving is dynamic5. The method of claim 4 , wherein the temperature of the aqueous solution is between +1 and +12° C.6. The method of claim 4 , wherein the dynamic perfusion comprises the step of perfusing the organ continuously.7. The method of claim 4 , wherein the dynamic perfusion comprises the step of perfusing the organ with a pulsatile flow.8. The method of claim 1 , wherein the rinsing step comprises the aqueous solution having a temperature between +1 and +12° C.9. The method of claim 1 , wherein the conditioning step involves comprises the aqueous solution having a temperature between +1 and +12° C.10. The method of claim 1 , wherein the organ to be transplanted is an abdominal organ comprising one or more the liver claim 1 , pancreas claim 1 , kidney or ...

LUNG PERFUSION SOLUTION, AND USE THEREOF FOR THE EX-VIVO PRESERVATION OF A MAMMALIAN LUNG

A lung perfusion solution comprises a base solution comprising a physiological mixture of electrolytes and buffers, 3.5-5.5% (w/v) a first macromolecule having a molecular weight of 40-100 KDa, and an amount of a second, high molecular weight, macromolecule sufficient to adjust the relative viscosity of the solution to 2.0-3.0. 1. An organ perfusion solution comprising: a base solution comprising a physiological mixture of electrolytes and buffers; and 3.5-5.5% (w/v) a first macromolecule having a molecular weight of 40-100 kDa , characterised in that the solution comprises an amount of a second , high molecular weight , macromolecule sufficient to adjust the relative viscosity of the solution to 2.0-3.0.2. An organ perfusion solution of claim 1 , in which the solution comprises an amount of a second claim 1 , high molecular weight claim 1 , macromolecule sufficient to adjust the relative viscosity of the solution to about 2.5.3. An organ perfusion solution of claim 1 , in which the solution comprises an amount of a second claim 1 , high molecular weight claim 1 , macromolecule sufficient to adjust the relative viscosity of the solution to about 2.5 and in which the second claim 1 , high molecular weight claim 1 , macromolecule has a molecular weight of 350-450 kDa.4. An organ perfusion solution of claim 1 , in which the second claim 1 , high molecular weight claim 1 , macromolecule is a branched polysaccharide-based polymer.5. An organ perfusion solution of claim 1 , in which the second claim 1 , high molecular weight claim 1 , macromolecule is non-ionic.6. An organ perfusion solution of claim 1 , in which the second claim 1 , high molecular weight claim 1 , macromolecule is a FICOLL PM400.7. An organ perfusion solution of claim 1 , in which the second claim 1 , high molecular weight claim 1 , macromolecule is provided in an amount of 2-5% (w/v).8. An organ perfusion solution of claim 1 , in which the first macromolecule is a molecule having a molecular weight of ...

METHODS AND COMPOSITIONS FOR VEIN HARVEST AND AUTOGRAFTING

The leading cause of graft failure is the subsequent development of intimal hyperplasia, which represents a response to injury that is thought to involve smooth muscle proliferation, migration, phenotypic modulation, and extracellular matrix (ECM) deposition. Surgical techniques typically employed for vein harvest—stretching the vein, placing the vein in low pH, solutions, and the use of toxic surgical skin markers—are shown here to cause injury. The invention therefore provides for non-toxic surgical markers than also protect against stretch-induced loss of functional viability, along with other additives. Devices and compositions for reducing physical stress or protecting from the effects flowing therefrom, also are provided. 149-. (canceled)50. A method of treating a tissue prior to transplant comprising: (a) providing a tissue; and (b) contacting a tissue with a P2Xreceptor antagonist in a buffered solution to produce a tissue; whereby functional viability of the stabilized tissue is preserved or restored.51. The method of claim 50 , wherein the said buffered solution is at pH7.0-7.6.52. The method of claim 50 , wherein said buffered solution further comprises heparin.53. The method of claim 51 , wherein said buffered solution comprises (i) heparin and (ii) erioglaucine/Blue Dye #1 and/or brilliant blue G.54. The method of claim 50 , wherein said buffered solution comprises phosphate buffered saline claim 50 , MOPS claim 50 , Hepes claim 50 , Pipes claim 50 , acetate or Plasmalyte.55. The method of claim 50 , wherein said buffered solution further comprises one or more of an anti-contractile agent claim 50 , an anti-oxidant agent claim 50 , an oligosaccharide claim 50 , a colloid agent claim 50 , an anti-inflammatory agent claim 50 , an endothelial function preservative claim 50 , a metabolic regulator claim 50 , a hydrogel claim 50 , an inhibitor of heat shock protein 27 (HSP27) claim 50 , a regulator of HSP20 claim 50 , and/or an inhibitor of MAPKAP kinase 2. ...

FLUID FOR SUSPENDED ANIMATION

A method to increase the time a donated organ will remain viable prior to transplantation, where the method includes infusing into a human patient declared brain dead, using a first intravenous line, a fluorocarbon fluid comprising a chain length from 1 to about 20 carbon atoms, and optionally synchronously with said infusing, exsanguinating said patient using a second intravenous line. 121-. (canceled)22. A method to increase the time one or more donated organs will remain viable prior to transplantation , comprising: after a decision is made to terminate life-support for a human patient declared brain dead ,providing an emulsion consisting of dodecafluoropentane 2% w/vol in water;nebulizing the emulsion with 100 percent oxygen;infusing using a first intravenous line the patient with the emulsion over thirty minutes at a dose of 0.6 cc per kilogram;synchronously with the infusing, exsanguinating the patient using a second intravenous line and ventilating the patient with oxygen;harvesting the one or more organs; andflushing the harvested one or more organs with the emulsion.23. A method to increase the time one or more donated organs will remain viable prior to transplantation , comprising:forming an emulsion consisting essentially of dodecafluoropentane in combination with an aqueous solution comprising sodium ions, potassium ions, calcium ions and magnesium ions;nebulizing the emulsion fluid with 100 percent oxygen;infusing using a first intravenous line the patient with the emulsion;synchronously with the infusing, exsanguinating the patient using a second intravenous line and ventilating the patient with oxygen;harvesting the one or more organs; andflushing the harvested one or more organs with the emulsion.24. A method to increase the time one or more donated organs will remain viable prior to transplantation , comprising:flushing organs harvested from a donor with a fluorocarbon fluid comprising a chain length from 1 to about 20 carbon atoms;after the ...

Systems and Methods for Ex Vivo Organ Care

The invention, in various embodiments, provides systems, methods and solutions for perfusing an organ ex vivo. 1. A method for evaluating a lung for transplant suitability comprising:positioning the lung in an ex vivo perfusion circuit,flowing a perfusion fluid into the lung through a pulmonary artery interface and flowing the perfusion fluid away from the lung through a pulmonary vein interface, the perfusion fluid being at a physiologic temperature,providing a gas to the lung through a tracheal interface,measuring a first composition of a gas component in the perfusion fluid, andperforming an evaluation on the lung based on the first composition.2. The method of claim 1 , wherein the perfusion fluid has a physiologic venous composition.3. The method of claim 1 , wherein the flow of the gas through the tracheal interface comprises about 100% oxygen.4. The method of claim 1 , wherein the flow of the gas through the tracheal interface comprises ambient air.5. The method of claim 1 , wherein the evaluation includes measuring a fractional inspired oxygen concentration.6. The method of claim 1 , wherein the evaluation includes measuring an arterial-venous (AV) oxygen gradient between the perfusion fluid flowing into the lung and the perfusion fluid flowing away from the lung.7. The method of claim 1 , wherein the evaluation includes measuring an alveolar arterial (AA) oxygen gradient.8. The method of claim 1 , wherein the evaluation includes measuring a tidal volume.9. The method of claim 1 , wherein the evaluation includes measuring at least one of a level of oxygen saturation of blood hemoglobin and a partial pressure of oxygen in the perfusion fluid flowing into the lung.10. The method of claim 1 , wherein the evaluation includes measuring at least one of a level of oxygen saturation of blood hemoglobin and a partial pressure of oxygen in the perfusion fluid flowing away from the lung.11. The method of claim 1 , wherein the evaluation includes measuring a positive ...

Apparatuses, Compositions, and Methods for Prolonging Survival of Platelets

The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets. The invention also provides methods for making a pharmaceutical composition containing the modified platelets and for administering the pharmaceutical composition to a mammal to mediate hemostasis. 1. An apparatus for processing a sample of platelets , the apparatus comprising a first sterile container having one or more ports including a first container port and containing a preparation of blood cells comprising platelets , a second sterile container having one or more ports including a second container port and containing a blood cell modifying agent which comprises cytidine 5′-monophospho-N-acetylneuraminic acid , the first container being adapted to the second container through a first sterile conduit reversibly attachable to the first container port and the second container port , the first sterile conduit further comprising a valve , wherein the blood cell modifying agent present in the second sterile container is introduced into the first sterile container and the platelets in the preparation of blood cells therein are rendered cold storage competent after the platelets are contacted with the blood cell modifying agent.2. The apparatus of claim 1 , further comprising a third sterile container having one or more ports including a third container port adapted to the first container through a second sterile conduit reversibly attachable to the first container port and the third container port claim 1 , the second sterile conduit further comprising a valve.3. The apparatus of claim 1 , wherein the first sterile conduit is adapted to an in-line filter having a median pore diameter small enough to substantially prevent the flow of bacteria through the in-line filter.4. The apparatus of claim 1 , wherein the first container claim 1 , second container claim 1 , the third ...

Erythrocyte Preservation Method

A method for preserving erythrocytes comprising the steps of obtaining an erythrocyte concentrate; subjecting the erythrocyte concentrate to a gas system that includes 65% to 100% by volume and optionally one or more ballast gases from 0% to 35% by volume; and, maintaining the erythrocyte concentrate that has been subjected to the gas system at a temperature that is above the freezing point of the erythrocyte concentrate and up to a temperature of about 30° C. 1. A method for preserving erythrocytes comprising the steps of:a. obtaining an erythrocyte concentrate;b. subjecting the erythrocyte concentrate to a gas system that includes xenon at a concentration that is greater than xenon gas that naturally occurs in the atmosphere; and,c. maintaining the erythrocyte concentrate that has been subjected to the gas system at a temperature that is above the freezing point of the erythrocyte concentrate and up to a temperature of about 30° C.2. The method as defined in claim 1 , wherein said gas system includes 65% to 100% by volume xenon and 0-35% by volume of at least one ballast gas.3. The method as defined in claim 1 , wherein said gas system includes less than 5% by volume oxygen.4. The method as defined in claim 1 , further including the step of removing 70-100% of the oxygen from the erythrocyte concentrate prior to adding said gas system to said erythrocyte concentrate.5. The method as defined in claim 4 , wherein said step of removing oxygen occurs in a vacuum environment.6. The method as defined in claim 1 , wherein said gas system is added to said erythrocyte concentrate at a pressure of about 1-10 atm.7. The method as defined in claim 6 , wherein said gas system is added to said erythrocyte concentrate at a pressure of above 1 atm.8. The method as defined in claim 1 , wherein said container is absent DEHP plasticizer.9. The method as defined in claim 1 , further including the step of agitating said erythrocyte concentrate in a container a) prior to addition of ...

Compositions and Methods for Stabilizing Circulating Tumor Cells

Compositions and Methods for Stabilizing Circulating Tumor Cells Methods and compositions for stabilizing a biological sample for analysis, comprising the steps of obtaining in a sample collection device a biological sample from a subject, especially blood, the biological sample including at least one circulating tumor cell from the subject. The methods may include a step of contacting the biological sample with a protective agent composition that includes a preservative agent, an optional anticoagulant, and a quenching agent to form a mixture that includes the protective agent composition and the sample. 1. A method for blood sample treatment comprising:locating a protective agent into a tube, the protective agent including imidazolidinyl urea and EDTA;drawing a blood sample having a first circulating tumor cell concentration into the tube, whereby the blood sample contacts the protective agent; wherein the concentration of the imidazolidinyl urea after the contacting step is greater than 5 mg/ml;', 'wherein the protective agent is present in an amount that is less than about 5% of an overall mixture volume of the protective agent and the drawn blood sample., 'isolating circulating tumor cells from the contacted sample after the blood draw, the contacted blood sample having a second circulating tumor cell concentration, wherein the second circulating tumor cell concentration is not lower or higher than the first circulating tumor cell concentration by any statistically significant value; and'}220-. (canceled)21. The method of claim 1 , wherein a concentration of the imidazolidinyl urea prior to the contacting step is between about 0.1 g/ml and about 3 g/ml.22. The method of claim 1 , wherein the circulating tumor cells are isolated from the contacted blood sample at least 1 day after the blood draw.23. The method of claim 1 , wherein the circulating tumor cells are isolated from the contacted blood sample at least 3 days after the blood draw.24. The method of claim ...

METHOD OF MAINTAINING OVARIES OF MARINE FISH, METHOD OF ADJUSTING CULTURE SOLUTION, AND METHOD OF PRODUCING EGGS OR FERTILIZED EGGS OF MARINE FISH

Provided are a method of maintaining the ovaries of marine fish, and a method of obtaining fertilized egg. Provided is a method of maintaining ovaries in which the ovaries are removed from marine fish and the ovaries or fragmented ovaries are cultured in a culture solution. Also, provided is a method of obtaining fertilized eggs of marine fish, the method including allowing ovaries, which have been maintained after removal to ovulate and performing artificial insemination. Further, the present invention relates to a method of maintaining the fertilization capability of ovulated eggs of marine fish by using the culture solution. According to the present invention, fertilized eggs of marine fish can be easily obtained and seed can be efficiently produced. 1: A method of maintaining ovaries of marine fish , the method comprising removing ovaries from marine fish , and culturing the removed ovaries or fragmented ovaries in a culture solution.2: The method according to claim 1 , wherein eggs contained in the ovaries are maintained in a fertilizable state.3: The method according to claim 1 , wherein the ovaries are ovaries containing oocytes.4: The method according to claim 1 , wherein a pH of the culture solution is adjusted to within a range from +0.5 to −0.5 relative to a pH of ovarian cavity fluid of the fish from which the ovaries have been removed.5: The method according to claim 1 , wherein an osmotic pressure of the culture solution is not less than 100 mOsm/kg and not greater than 6000 mOsm/kg.6: The method according to claim 1 , wherein the culture solution comprises at least one selected from the group consisting of sodium ions claim 1 , potassium ions claim 1 , calcium ions claim 1 , and magnesium ions.7: The method according to claim 6 , wherein a sodium ion concentration of the culture solution is not less than 120 mM and not greater than 250 mM.8: The method according to claim 6 , wherein a potassium ion concentration of the culture solution is not less ...

TRANSDUCED CELL CRYOFORMULATION

The invention relates to compositions for the cryopreservation of transduced haematopoietic cells, in particular transduced haematopoietic stem cells. The invention also relates to methods of preserving the viability of transduced haematopoietic cells using said compositions. 1. A composition comprising a transduced haematopoietic cell in a cryoprotective formulation , wherein the cryoprotective formulation comprises about 5% by volume of dimethyl sulfoxide (DMSO) and about 7% weight by volume of human serum albumin (HSA).2. The composition of claim 1 , wherein the haematopoietic cell is a haematopoietic stem cell.3. The composition of claim 2 , wherein the haematopoietic stem cell is selected from a CD34+ haematopoietic stem cell or a CD34+CD38− haematopoietic stem cell.4. The composition of claim 1 , wherein the haematopoietic cell is allogeneic or autologous.5. The composition of claim 1 , wherein the haematopoietic cell is transduced with a lentiviral vector.6. The composition of claim 1 , wherein the haematopoietic cell contains a transgene encoding arylsulfatase A or a fragment or derivative thereof.7. The composition of claim 1 , which is formulated in 0.9% saline solution.8. A method for preserving the viability of transduced haematopoietic cell claim 1 , the method comprising:(a) obtaining a plurality of transduced haematopoietic cells;(b) suspending the transduced haematopoietic cells in a cryoprotective medium comprising about 5% by volume of dimethyl sulfoxide (DMSO) and about 7% weight by volume of human serum albumin (HSA), to form a suspension; and(c) freezing the suspension.9. The method of claim 8 , wherein step (a) comprises: (i) obtaining a plurality of haematopoietic cells; and (ii) transducing the haematopoietic cells with a viral vector.10. The method of claim 8 , wherein the haematopoietic cells are obtained from the patient or a donor.11. The method of claim 8 , wherein the haematopoietic cells are transduced with a lentiviral vector.12. The ...

ALPHA CONNEXIN C-TERMINAL (ACT) PEPTIDES FOR USE IN TRANSPLANT

The present disclosure provides compositions and methods for treating or preventing macular degeneration in a subject. The disclosure also provides compositions and methods for preserving organs and tissues for transplantation, and for preventing cellular injury in organs or in subjects. 1. A method of treating a stroke in a subject in need thereof , the method comprising administering to the subject a composition comprising an isolated polypeptide comprising the carboxy terminal-most 4 to 30 contiguous amino acids of an alpha Connexin.2. The method of claim 1 , wherein the method prevents or treats ischemia and reperfusion injury following the stroke.3. The method of claim 1 , wherein the stroke is a hemorrhagic stroke or a cerebral stroke.4. The method of claim 1 , wherein the polypeptide comprises the carboxy terminal-most 5 to 19 contiguous amino acids of the alpha Connexin.5. The method of claim 1 , wherein the composition is administered topically claim 1 , orally claim 1 , intracranially claim 1 , intravaginally claim 1 , intraanally claim 1 , subcutaneously claim 1 , intradermally claim 1 , intracardiac claim 1 , intragastric claim 1 , intravenously claim 1 , intramuscularly claim 1 , by intraperitoneal injection claim 1 , transdermally claim 1 , intranasally claim 1 , or by inhalant.6. The method of claim 1 , wherein the composition is coated on a medical implant.7. The method of claim 1 , wherein the alpha Connexin is selected from a group consisting of Connexin 30.2 claim 1 , Connexin 31.9 claim 1 , Connexin 33 claim 1 , Connexin 35 claim 1 , Connexin 36 claim 1 , Connexin 37 claim 1 , Connexin 38 claim 1 , Connexin 39 claim 1 , Connexin 39.9 claim 1 , Connexin 40 claim 1 , Connexin 40.1 claim 1 , Connexin 43 claim 1 , Connexin 43.4 claim 1 , Connexin 44 claim 1 , Connexin 44.2 claim 1 , Connexin 44.1 claim 1 , Connexin 45 claim 1 , Connexin 46 claim 1 , Connexin 46.6 claim 1 , Connexin 47 claim 1 , Connexin 49 claim 1 , Connexin 50 claim 1 , Connexin 56 ...

ORGAN AND TISSUE PRESERVATION SOLUTIONS HAVING INCREASED OXYGEN-CONTENT, STABILITY AND SHELF LIFE

Organ and tissue preservation solutions having improved formulations are comprised of two separate solutions. The first solution includes one or more salts, water, dissolved oxygen, lactobionic acid, mannitol, glutamic acid and histidine at a pH of at least 7, preferably from about 7.3 to about 8.3. The second solution includes water and reduced glutathione at a pH of below 7.0, preferably from about 3 to 6 wherein oxygen present in the solution is removed. The two formulations are mixed together at the point of use resulting in an organ and tissue preservation solution having improved stability and that contains oxygen to prevent ischemia in the preserved organs. The present invention also includes kits that contain the two formulations. 1. An organ and preservation kit comprised of a first aqueous solution contained in a first container and a second solution contained in a second container wherein the first aqueous solution comprises one or more salts , water , dissolved oxygen , lactobionic acid and glutamic acid and said first solution has a pH of at least 7.0; and wherein the second solution comprises water , reduced glutathione and said second solution has a pH of below 7 and wherein the second solution is substantially free of oxygen.2. The kit of wherein the first and second containers are first and second chambers contained within a single container and the first and second chambers are partitioned off from each other by a partition claim 1 , wherein upon the removal of the partition claim 1 , the first solution mixes with the second solution to form the complete organ and tissue preservation solution.3. The kit of wherein the pH of the first solution is about from about 7.3 to about 8.3 and the pH of the second solution is from about 4 to about 6.4. The kit of wherein the second solution further comprises mannitol and histidine.5. A method for preparing an organ or tissue preservation solution comprising;combining a first solution comprising water, one or ...

Modulating ischemic injury and preserving/storing tissue

The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents. 120.-. (canceled)21. A method for modulating ischemic injury in donated tissues or organs that have been harvested for transplant , the method comprising the step of perfusing and/or immersing the donated tissue or organ with a composition comprising Amnion-derived Cellular Cytokine Solution (ACCS).22. The method of wherein the ACCS is formulated for sustained-release claim 21 , targeted-release claim 21 , timed-release claim 21 , or extended-release.23. The method of wherein the tissue is selected from the group consisting of epithelial tissue claim 21 , connective tissue claim 21 , muscle tissue and nervous tissue and the organ is selected from the group consisting of heart claim 21 , blood vessel claim 21 , alimentary canal claim 21 , stomach claim 21 , liver claim 21 , pancreas claim 21 , spleen claim 21 , kidney claim 21 , lung claim 21 , trachea claim 21 , cornea claim 21 , lens claim 21 , eye claim 21 , bladder claim 21 , ureter claim 21 , urethra claim 21 , uterus claim 21 , ovary claim 21 , testis claim 21 , nerve claim 21 , skin claim 21 , tooth claim 21 , and skeletal muscle.24. A method for reducing ischemic injury in donated tissues or organs that have been harvested for transplant claim 21 , the method comprising the step of perfusing and/or immersing the donated tissue or organ with a composition ...

SIMULATED ENVIRONMENT FOR TRANSCATHETER HEART VALVE REPAIR

An apparatus for applying liquid pressure to resected tissue may include a fixture, a papillary assembly coupled to the fixture and having first and second spaced apart papillary attachment elements, and a resected mitral valve attached to the fixture. The fixture may have a first chamber, a second chamber, and an internal panel extending between the first and second chambers. The resected mitral valve may be attached to the internal panel and may have a posterior leaflet, an anterior leaflet, and tendinae chordae. The tendinae chordae may each be attached at a first end to the posterior leaflet or the anterior leaflet and at a second end to one of the papillary attachment elements. A first group of the tendinae chordae may be attached to the first papillary attachment element, and a second group of the tendinae chordae may be attached to the second papillary attachment element. 1. A simulation apparatus for mounting resected tissue , the apparatus comprising:a fixture having a first chamber, a second chamber, and an internal panel extending between the first and second chambers;a papillary assembly coupled to the fixture and having first and second spaced apart papillary attachment elements, each papillary attachment element being movable relative to the internal panel in at least one degree of freedom;a resected mitral valve attached to the internal panel and having a posterior leaflet, an anterior leaflet, and tendinae chordae, the tendinae chordae each attached at a first end to the posterior leaflet or the anterior leaflet and at a second end to one of the papillary attachment elements; anda pumping system configured to provide liquid flow through the resected mitral valve, the pumping system configured to alternatingly provide high pressure liquid pulses into the first chamber and a back pressure into the second chamber, the back pressure being less than the high pressure liquid pulses.2. The apparatus as claimed in claim 1 , wherein the pumping system is a ...

PRESERVATION OF VASCULARIZED COMPOSITE ALLOGRAFTS

This disclosure relates to subnormothermic machine perfusion formulations for ex vivo preservation of allografts, and methods of use thereof. 1. A method for preserving a biological tissue sample , the method comprising:(a) perfusing the biological tissue sample with a hyperosmolar sub-normothermic perfusion solution comprising one or more cryoprotective agents, one or more oxygen carrier agents, one or more growth factors, and one or more vasodilators, at a sub-normothermic temperature;(b) perfusing the biological tissue sample with a subzero non-freezing preservation solution comprising at least one or more cryoprotective agents, at a hypothermic temperature;(c) optionally placing the perfused biological tissue sample in a container and sealing the container; and(d) cooling the biological tissue sample in the container to a subzero temperature without freezing the sample, thereby preserving the biological tissue sample at the subzero temperature.2. The method of claim 1 , further comprising:(e) warming the biological tissue sample to a hypothermic temperature;(f) perfusing the biological tissue sample with a recovery solution comprising one or more cryoprotective agents and one or more oxygen carrier agents at a sub-normothermic temperature; and(g) warming the biological tissue sample to a normothermic temperature, thereby recovering the preserved biological tissue sample for use.3. The method of claim 1 , wherein the method further comprises claim 1 ,preferably prior to step (a):removing hair from the biological tissue sample, sufficient to avoid ice crystal formation within the biological tissue sample or the perfusion solution, optionally wherein the hair is removed from the biological tissue sample by contacting the biological tissue sample with a chemical depilatory agent.4. (canceled)5. The method of claim 1 , wherein the sub-normothermic perfusion solution comprises one or more cryoprotective agents selected from polyethylene glycol (PEG) and 3-OMG claim 1 ...

CRYOPRESERVATION OF CELL-SEEDED SUBSTRATES AND RELATED METHODS

Disclosed herein are methods and compositions for the identification of viability enhancing cell features and substrate features as they relate to post-cryopreservation survival of substrate seeded cells. Embodiments of the present invention further involve identification of cell features to manufacture a supernatant that is useful for cell culturing and treatment of various diseases. 1. A method of cryopreserving cells on a substrate , the method comprising:providing a biocompatible polymer substrate seeded with a monolayer of immature retinal pigment epithelium (RPE) cells, the polymer substrate providing a cell seeding surface;identifying when i) the monolayer of immature RPE cells reaches between 90% and 99% confluence on the substrate and ii) most of the immature RPE cells are not fully pigmented;exposing, upon the identifying, the substrate seeded with cells to a controlled temperature reduction rate between about −1° C. per minute to about −30° C. per minute until a first temperature below −20° C. is reached;2. The method of claim 1 , wherein the cell-seeded substrate reaches a temperature below that which delineates a latent heat release of the seeded cells.3. The method of claim 2 , wherein a surface of the is substantially parallel to the monolayer of the immature RPE cells seeded on the substrate claim 2 , sufficient to induce nucleation and efficient temperature compensation in response to the latent heat release of the seeded cells.4. The method of claim 1 , further comprising:maintaining the cell-seeded substrate at the first temperature, the first temperature being between −20° C. to about −100° C. after the controlled temperature reduction rate for a first period of time to obtain uniformity of temperature; andmaintaining the cells at a storage temperature lower than the first temperature for a second period of time within 50° C. of the first temperature, thereby obtaining cryopreserved cells.5. The method of claim 1 , further comprising:maintaining ...

ISOLATED ADULT CELLS, ARTIFICIAL ORGANS, REHABILITATED ORGANS, RESEARCH TOOLS, ORGAN ENCASEMENTS, ORGAN PERFUSION SYSTEMS, AND METHODS FOR PREPARING AND UTILIZING THE SAME

One aspect of the invention provides a method for harvesting adult cells from an organ. The method includes perfusing the organ with a perfusate and isolating adult cells from the organ, thereby harvesting the adult cells from the organ. Another aspect of the invention provides a method for rehabilitating an organ. The method includes: dividing the organ into a first portion and a second portion, perfusing the first portion with a decellularization medium, isolating adult cells from the second portion, and recellularizing the first portion with a suspension of the adult cells, thereby rehabilitating the organ. 1. A method for harvesting adult cells from an organ , the method comprising:perfusing the organ with a perfusate; andisolating adult cells from the organ;thereby harvesting the adult cells from the organ.2. The method of claim 1 , wherein the organ is a mammalian organ.3. The method claim 2 , wherein the organ is a human organ.45-. (canceled)6. The method of claim 1 , wherein the organ is one selected from the group consisting of: pancreas claim 1 , spleen claim 1 , heart claim 1 , lung claim 1 , and kidney.7. The method of claim 1 , wherein the organ is ischemic and/or wherein the organ is a damaged organ.8. The method of claim 1 , wherein the perfusate includes one or more oxygen carriers claim 1 , wherein the one or more oxygen carriers comprises erythrocytes.9. (canceled)10. The method of claim 1 , wherein the perfusate includes one or more anti-inflammatory agents claim 1 , wherein the one or anti-inflammatory agents comprises hydrocortisone.11. (canceled)12. The method of claim 1 , wherein the perfusate comprises collagenase.13. The method of claim 1 , wherein the perfusate is a normothermic perfusate claim 1 , a room temperature perfusate claim 1 , or a hypothermic perfusate.1415-. (canceled)16. The method of claim 1 , further comprising culturing the harvested adult cells.17. The method of claim 1 , further comprising providing the organ.18. The ...

COMPOSITIONS AND METHODS FOR GENERATING MODIFIED CRYO POOR PLASMA

A method for producing a modified cryo-poor precipitate that can be utilized in chromatography without intervening precipitation steps is provided. While thawing frozen plasma at low temperature a precipitating compound (e.g. a salt of an organic acid) is added in small amounts. The resulting modified cryo-poor plasma has a reduced tendency to foul chromatography media, permitting direct application to such media without the need for additional precipitation steps. The resulting modified cryoprecipitate has a higher content of cold-insoluble proteins (such as clotting factors), and can be resolubilized and processed further. 1. A method of providing a modified cryo-poor plasma , comprising:obtaining a first volume of frozen plasma;thawing the first volume of frozen plasma at a temperature of from about 1° C. to about 6° C. to generate a thawing plasma;adding an amount of a precipitant to the thawing plasma to generate a modified cryoprecipitate and a modified cryo-poor plasma, wherein the amount is selected to not generate a precipitate when the amount of the precipitant is added to a second volume of thawed plasma, wherein the second volume is equivalent to the first volume; andseparating the modified cryoprecipitate from the modified cryo-poor plasma.2. The method of claim 1 , wherein the precipitant is selected from the group consisting of an organic acid claim 1 , a salt of an organic acid claim 1 , an inorganic salt claim 1 , and a hydrophilic polymer.3. The method of claim 1 , wherein the precipitant is sodium citrate.4. The method of claim 1 , wherein the modified cryoprecipitate has an increased content of cold-insoluble proteins relative to a conventional cryoprecipitate generated by thawing the frozen plasma at a temperature of from about 1° C. to about 6° C. in the absence of the precipitant.5. The method of claim 1 , wherein the modified cryo-poor plasma has a decreased content of cold-insoluble proteins or denatured proteins relative to a conventional ...

FORMULATIONS CONTAINING POLY (0-2 HYDROXYETHYL) STARCH FOR INCREASING THE OXYGEN-CONTENT, STABILITY AND SHELF LIFE OF AN ORGAN AND TISSUE PRESERVATION SOLUTION

Organ and tissue preservation solutions having improved formulations. The improved solutions are comprised of two separate solutions. The first solution, is comprised of one or more salts, water, dissolved oxygen, Poly (0-2-hydroxyethyl) starch, lactobionic acid, adenosine, raffinose and allopurinol and said first solution has a pH of at least 7.0;, preferably from about 7.3 to about 8.2; and a second solution comprised of water, and reduce glutathione at a pH of below 7.0, preferably from about 3 to 6 wherein oxygen present in the solution is removed. The two formulations are then mixed together at the point of use resulting in the organ and tissue preservation solution having improved stability and that contains oxygen to prevent ischemia in the preserved organs. The present invention is also comprised of kits that contain the two formulations. 1. An organ and preservation kit comprised of a first aqueous solution contained in a first container and a second solution contained in a second container wherein the first aqueous solution is comprised of a one or more salts , water , dissolved oxygen , Poly (0-2-hydroxyethyl) starch , and at least one of lactobionic acid , adenosine , raffinose and allopurinol and said first solution has a pH of at least 7.0; wherein the second solution is comprised of water , reduced glutathione and said second solution has a pH of below 7 and the second solution contains substantially no oxygen.2. The kit of wherein the first and second containers are first and second chambers of a single container and the first and second chambers are separated by a removable partition claim 1 , wherein upon the removal of the partition claim 1 , the first solution mixes with the second solution to form the complete organ and tissue preservation solution.3. The kit of wherein the pH of the first solution is about from about 7.3 to about 8.2 and the pH of the second solution is from about 3 to about 6.4. A method for preparing an organ or tissue ...

TISSUE PRESERVATION SYSTEM

The present invention provides a method and apparatus for tissue, such as an allograft, storage and preservation for extended periods of time at room temperature in a sterile tissue culture chamber. The invention further provides a process for maintaining the sterility of tissue using the apparatus as described. 1. A process for tissue preservation comprising storing the tissue at room temperature in a container comprising culture media for from about 7 to about 70 days prior to implantation.2. The process of claim 1 , comprising testing the tissue for viability at least once prior to implantation in a patient.3. The process of claim 2 , wherein testing for viability comprises assaying media withdrawn from said container.4. The process of claim 2 , wherein testing for viability comprises adding a resazurin solution to the media and determining the fluorescence level claim 2 , wherein increased fluorescence indicates higher cell viability.5. The process of claim 1 , comprising storing the tissue for from 29 to about 70 days.6. The process of comprising changing said media at least once during the storing.7. The process of claim 6 , comprising changing the media about once every two weeks during the storing.8. The process of claim 1 , wherein at least about 70% of tissue preserved by said process remain viable after 45 days of storing.9. The process of claim 1 , wherein the media is serum free media.10. The process of claim 9 , wherein the media comprises Dulbecco's Modified Eagle Medium (DMEM) claim 9 , high or low concentrations of glucose claim 9 , antibiotic compounds (i.e. claim 9 , penicillin and/or streptomycin) claim 9 , antimycotic compounds (i.e. claim 9 , Fungizone) claim 9 , dexamethasone claim 9 , ascorbate 2-phosphate claim 9 , L-proline claim 9 , sodium pyruvate claim 9 , TGF-β3 claim 9 , and insulin claim 9 , transferrin claim 9 , and selenous acid claim 9 , among other chemicals or compounds.11. The process of claim 1 , comprising storing the tissue ...

Administration And Monitoring Of Nitric Oxide In Ex Vivo Fluids

Described are systems and methods for monitoring administration of nitric oxide (NO) to ex vivo fluids. Examples of such fluids include blood in extracorporeal membrane oxygenation (ECMO) circuits or perfusion fluids used for preserving ex vivo organs prior to transplanting in a recipient. The systems and methods described herein provide for administering nitric oxide to the fluid, monitoring nitric oxide or a nitric oxide marker in the fluid, and adjusting the nitric oxide administration. 1. A method of preserving a liver for transplant , the method comprising:persufflating a liver with a persufflation gas comprising nitric oxide (NO);monitoring one or more persufflation parameters in (i) the liver and/or (ii) a preservation fluid used to store the liver during persufflation, wherein the one or more persufflation parameters is selected from the group consisting of NO, a NO marker, an indicator of tissue damage, and combinations thereof; andadjusting the amount of NO provided to the liver by the persufflation gas based on the monitoring of the one or more persufflation parameters.2. The method of claim 1 , wherein the concentration of NO in the persufflation gas is in the range from 0.1 ppm to 300 ppm.3. The method of claim 1 , wherein the persufflation gas further comprises oxygen.4. The method of claim 1 , wherein the one or more persufflation parameters is monitored continuously.5. The method of claim 1 , further comprising perfusing the liver with a perfusion fluid comprising NO and/or a NO donor.6. The method of claim 5 , further comprising:monitoring one or more perfusion parameters in (i) the liver and/or (ii) the perfusion fluid, wherein the one or more perfusion parameters is selected from the group consisting of NO, a NO marker, an indicator of tissue damage, and combinations thereof; andadjusting the amount of NO and/or NO donor provided to the liver by the perfusion fluid based on the monitoring of the one or more perfusion parameters.7. The method of ...

SOLUTION FOR PRESERVING AND/OR RINSING AN ORGAN TO BE TRANSPLANTED

This invention relates to an aqueous solution for preserving and rinsing organs to be transplanted comprising: 1. An aqueous solution for preserving and/or rinsing organs to be transplanted comprising:{'sup': +', '−1, 'sodium (Na) ions at a concentration between 30 and 150 mmol.L;'}{'sup': +', '−1, 'potassium ions (K) at a concentration between 10 and 40 mmol.L;'}{'sup': −1', '−1, 'polyethylene glycol with a molecular weight of 35,000 g.mol(PEG 35000) at a concentration between 2 and 5 g.L.'}2. The solution of claim 1 , further comprising glutathione claim 1 , as an antioxidant agent claim 1 , at a concentration between 1 and 11 mmol.L.3. The solution of claim 1 , further comprising zinc ions (Zn) at a concentration between 0.170 and 0.210 mmol.L.4. The solution of further comprising nitrite ions (NO) at a concentration between 5 and 100 nmol.L.5. The solution of claim 1 , wherein the solution has a pH between 7.2 and 7.6.6. The solution of further comprising an impermeable anion claim 1 , a sugar claim 1 , a cell membrane stabilizer claim 1 , a buffer solution claim 1 , and/or an energy source.7. The solution of further comprising:{'sup': −1', '−1, 'raffinose at a concentration between 25 and 35 mmol.Land allopurinol at a concentration between 0.5 and 1.5 mmol.L; or'}{'sup': '−1', 'mannitol at a concentration between 40 and 80 mmol.L, or'}{'sup': −1', '−1, 'mannitol at a concentration between 40 and 80 mmol.Land histidine at a concentration between 25 and 35 mmol.L.'}8. The solution of further comprising:{'sup': '−1', 'lactobionic acid at a concentration between 80 and 120 mmol.L;'}{'sub': '4', 'sup': 2−', '−1, 'sulphate ions (SO) at a concentration between 4 and 6 mmol.L;'}{'sub': '4', 'sup': 3−', '−1, 'phosphate ions (PO) at a concentration between 20 and 30 mmol.L; and'}{'sup': '−1', 'adenosine at a concentration between 4 and 6 mmol.L.'}9. The solution of further comprising:{'sup': '−1', 'PEG 35000 at a concentration of 5 g.L;'}{'sup': '−1', 'glutathione at a ...

CANNULA

A method of cannulating vasculature includes inserting the vasculature through a first clamping surface of a cannula and rotating a second clamping surface of the cannula around the first clamping surface to move from an open position towards a closed position. Additionally, the method includes securing the vasculature between the first clamping surface and the second clamping surface. 1. A method of cannulating vasculature , comprising:inserting the vasculature through a first clamping surface of a cannula;rotating a second clamping surface of the cannula around the first clamping surface to move from an open position towards a closed position; andsecuring the vasculature between the first clamping surface and the second clamping surface.2. The method according to claim 1 , further including perfusing an organ or tissue through the secured vasculature.3. The method according to claim 1 , further including securing the cannula in the closed position with a latch.4. The method according to claim 3 , wherein the latch exerts a force urging the first clamping surface and the second clamping surface together when in the closed position.5. The method according to claim 1 , wherein the cannula includes a connecting structure that allows the second clamping surface to rotate towards the closed position.6. The method according to claim 5 , wherein the second clamping surface is attached to a base and the connecting structure biases the second clamping surface toward and away from the base.7. The method according to claim 1 , wherein the second clamping surface is rotatable 360°.8. The method according to claim 1 , further including attaching a handle to the cannula.9. The method according to claim 9 , wherein the second clamping surface is rotatable about the handle in the open position and the second clamping surface is not rotatable about the handle in the closed position.10. The method according to claim 9 , further including removing the handle from the cannula while ...

Compositions and Methods for Preservation and Fixation

The present inventive concept provides non-toxic compositions including ethanol, a polymer, and a polar aprotic solvent and methods of using the same in the field of preservation of plant, human and non-human animal tissue and anatomic pathology disciplines (e.g., surgical pathology, histopathology, cytopathology, forensic pathology). In particular, the compositions provide a safer alternative to aldehyde-based compositions. 1. A tissue preservative comprising ethanol , a polymer , and a polar aprotic solvent.2. The tissue preservative of claim 1 , wherein the tissue preservative is essentially free of an aldehyde.3. The tissue preservative of claim 1 , wherein the tissue preservative is essentially free of formaldehyde claim 1 , formalin claim 1 , formic aldehyde claim 1 , glutaraldehyde claim 1 , methanol claim 1 , methanediol claim 1 , methanal claim 1 , methyl aldehyde claim 1 , methylene glycol and/or methylene oxide.4. The tissue preservative of claim 1 , wherein the polymer is selected from the group consisting of propylene glycol claim 1 , diethylene glycol claim 1 , dipropylene glycol claim 1 , polyethylene glycol claim 1 , 1 claim 1 ,3-propanediol claim 1 , ethylene glycol claim 1 , and combinations thereof.5. (canceled)6. The tissue preservative of claim 1 , wherein the polar aprotic solvent is selected from the group consisting of isopropyl ethyl acetate claim 1 , dichloromethane claim 1 , tetrahydrofuran claim 1 , ethyl acetate claim 1 , dimethylformamide claim 1 , acetonitrile and combinations thereof.7. The tissue preservative of claim 1 , further comprising a humectant claim 1 , an antimicrobial agent claim 1 , a chelating agent claim 1 , a fragrance claim 1 , an emollient and/or a color additive.810-. (canceled)11. The tissue preservative of claim 1 , wherein the tissue preservative is an aqueous solution.12. The tissue preservative of claim 1 , wherein the tissue preservative is non-toxic and/or environmentally safe.13. The tissue preservative of ...

PACKAGING SYSTEM FOR A MEDICAL PRODUCT

A packaging system includes a holder and an inner container. The holder includes a top portion and a bottom portion that cooperate to form a cavity configured to receive one or more medical products therein and to retain the one or more medical products therein. The inner container defines an interior region configured to receive the holder therein. The holder includes sidewalls that form the cavity, and the sidewalls include channels configured to fluidly connect the cavity to the interior region of the inner container. 1. A packaging system , comprising:a holder, including a top portion and a bottom portion that cooperate to form a cavity configured to receive one or more medical products therein and to retain the one or more medical products therein; andan inner container, wherein the inner container defines an interior region configured to receive the holder therein,wherein the holder includes sidewalls that form the cavity, and wherein the sidewalls include channels configured to fluidly connect the cavity to the interior region of the inner container.2. The packaging system of claim 1 , wherein the inner container includes an inner tray that includes a first portion and a second portion claim 1 , wherein the first portion and the second portion each include an interlocking portion that forms a seal when coupled together.3. The packaging system of claim 1 , further comprising:an outer container, wherein the outer container includes a well configured to receive the inner container therein.4. The packaging system of claim 1 , wherein the channels are formed by extensions and indentations in the sidewalls.5. The packaging system of claim 4 , wherein the extensions and indentations in the sidewalls are rounded.6. The packaging system of claim 1 , wherein at least one of the holder claim 1 , the inner container claim 1 , or the outer container is formed of a plastic material and/or via thermoforming.7. The packaging system of claim 1 , wherein the inner container is ...

HANDLING OF BIOLOGICAL SAMPLES

The present invention relates to the handling of biological samples, for example, the holding, manipulating and culturing of biological samples. In one form the invention provides an overlay encapsulant for an in vitro cell culture comprising a synthetic compound and in another aspect the invention provides methods of temporarily encapsulating an in vitro cell culture comprising a synthetic compound. The invention has use in relation to the culturing and more particularly the encapsulation of biological samples, such as for example zygotes, embryos, oocytes, stem cells, sperm located in a culturing space, relevant pluripotent derivative(s) and/or differentiated progeny, intact or dispersed tissue and/or intact organism(s). 1. An overlay encapsulant for an in vitro cell culture comprising a synthetic compound.2. An overlay encapsulant according to wherein the cell culture comprises one or more cells in a culture media.3. An overlay encapsulant according to wherein the one or more cells comprises at least one or a combination of:ovum;zygote;embryo;animal/human-derived embryonic stem cell(s);relevant pluripotent derivative(s) and/or differentiated progeny;intact or dispersed tissue and/or intact organism.4. An overlay encapsulant according to wherein the synthetic compound is a synthetic small molecule composition exhibiting unequivocal chemical composition as identified via conventional analytical techniques within limits of detection and comprising one or a combination of.synthetic monomer(s);oligomers or polymers;chemical derivatives and/or copolymers of polyalphaolefins,each exhibiting specific chemical, biophysical and spectroscopic properties.5. An overlay encapsulant according to wherein the synthetic compound comprises at least one hydrocarbon.6. An overlay encapsulant according to wherein the synthetic compound comprises a modified hydrocarbon.7. An overlay encapsulant according to wherein the modified hydrocarbon comprises a fluorinated hydrocarbon.8. An ...